<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
    <journal-id journal-id-type="iso-abbrev">Proc Natl Acad Sci U S A</journal-id>
    <journal-id journal-id-type="hwp">pnas</journal-id>
    <journal-id journal-id-type="publisher-id">PNAS</journal-id>
    <journal-title-group>
      <journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0027-8424</issn>
    <issn pub-type="epub">1091-6490</issn>
    <publisher>
      <publisher-name>National Academy of Sciences</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9636908</article-id>
    <article-id pub-id-type="pmid">36306325</article-id>
    <article-id pub-id-type="publisher-id">202211194</article-id>
    <article-id pub-id-type="doi">10.1073/pnas.2211194119</article-id>
    <article-categories>
      <subj-group subj-group-type="hwp-journal-coll">
        <subject>419</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Biological Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Genome-wide detection of human variants that disrupt intronic branchpoints</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6129-567X</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Peng</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="cor1" ref-type="corresp">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Philippot</surname>
          <given-names>Quentin</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ren</surname>
          <given-names>Weicheng</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">
          <sup>d</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lei</surname>
          <given-names>Wei-Te</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Juan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Stenson</surname>
          <given-names>Peter D.</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">
          <sup>e</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Palacín</surname>
          <given-names>Pere Soler</given-names>
        </name>
        <xref rid="aff6" ref-type="aff">
          <sup>f</sup>
        </xref>
        <xref rid="aff7" ref-type="aff">
          <sup>g</sup>
        </xref>
        <xref rid="aff8" ref-type="aff">
          <sup>h</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Colobran</surname>
          <given-names>Roger</given-names>
        </name>
        <xref rid="aff8" ref-type="aff">
          <sup>h</sup>
        </xref>
        <xref rid="aff9" ref-type="aff">
          <sup>i</sup>
        </xref>
        <xref rid="aff10" ref-type="aff">
          <sup>j</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5240-3555</contrib-id>
        <name>
          <surname>Boisson</surname>
          <given-names>Bertrand</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Shen-Ying</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2603-0323</contrib-id>
        <name>
          <surname>Puel</surname>
          <given-names>Anne</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Pan-Hammarström</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref rid="aff4" ref-type="aff">
          <sup>d</sup>
        </xref>
        <xref rid="fn5" ref-type="author-notes">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Qian</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
        <xref rid="fn5" ref-type="author-notes">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8943-8484</contrib-id>
        <name>
          <surname>Cooper</surname>
          <given-names>David N.</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">
          <sup>e</sup>
        </xref>
        <xref rid="fn5" ref-type="author-notes">
          <sup>2</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Abel</surname>
          <given-names>Laurent</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
        <xref rid="fn6" ref-type="author-notes">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7782-4169</contrib-id>
        <name>
          <surname>Casanova</surname>
          <given-names>Jean-Laurent</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">
          <sup>a</sup>
        </xref>
        <xref rid="aff2" ref-type="aff">
          <sup>b</sup>
        </xref>
        <xref rid="aff3" ref-type="aff">
          <sup>c</sup>
        </xref>
        <xref rid="aff11" ref-type="aff">
          <sup>k</sup>
        </xref>
        <xref rid="fn6" ref-type="author-notes">
          <sup>3</sup>
        </xref>
        <xref rid="cor1" ref-type="corresp">
          <sup>1</sup>
        </xref>
      </contrib>
      <aff id="aff1"><sup>a</sup>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, <institution>The Rockefeller University</institution>, New York, NY 10065;</aff>
      <aff id="aff2"><sup>b</sup>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, <institution>INSERM UMR1163</institution>, 75015 Paris, <country>France</country>;</aff>
      <aff id="aff3"><sup>c</sup><institution>Paris Cité University, Imagine Institute</institution>, 75015 Paris, <country>France</country>;</aff>
      <aff id="aff4"><sup>d</sup>Department of Biosciences and Nutrition, <institution>Karolinska Institutet</institution>, 14183 Huddinge, <country>Sweden</country>;</aff>
      <aff id="aff5"><sup>e</sup>Institute of Medical Genetics, School of Medicine, <institution>Cardiff University</institution>, Cardiff CF14 4XN, <country>United Kingdom</country>;</aff>
      <aff id="aff6"><sup>f</sup>Infection in Immunocompromised Pediatric Patients Research Group, Vall d’Hebron Research Institute, Vall d’Hebron Barcelona Hospital Campus, <institution>Vall d’Hebron University Hospital</institution>, 08035 Barcelona, <country>Spain</country>;</aff>
      <aff id="aff7"><sup>g</sup>Pediatric Infectious Diseases and Immunodeficiencies Unit, Vall d’Hebron University Hospital, Vall d’Hebron Research Institute, Vall d’Hebron Barcelona Hospital Campus, <institution>Autonomous University of Barcelona</institution>, 08035 Barcelona, <country>Spain</country>;</aff>
      <aff id="aff8"><sup>h</sup><institution>Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies</institution>, 08035 Barcelona, <country>Spain</country>;</aff>
      <aff id="aff9"><sup>i</sup>Diagnostic Immunology Group, Vall d’Hebron Research Institute, Vall d’Hebron Barcelona Hospital Campus, <institution>Vall d’Hebron University Hospital</institution>, 08035 Barcelona, <country>Spain</country>;</aff>
      <aff id="aff10"><sup>j</sup>Immunology Division, Genetics Department, <institution>Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Autonomous University of Barcelona</institution>, 08035 Barcelona, <country>Spain</country>;</aff>
      <aff id="aff11"><sup>k</sup><institution>HHMI</institution>, New York, NY 10065</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><sup>1</sup>To whom correspondence may be addressed. Email: <email>pzhang@rockefeller.edu</email> or <email>casanova@rockefeller.edu</email>.</corresp>
      <fn id="fn1" fn-type="edited-by">
        <p>Contributed by Jean-Laurent Casanova; received June 30, 2022; accepted September 14, 2022; reviewed by William Fairbrother and Stylianos Antonarakis</p>
      </fn>
      <fn id="fn2" fn-type="con">
        <p>Author contributions: P.Z., L.A., and J.L.-C. designed research; P.Z., Q.P., and W.R. performed research; P.Z., W.-T.L., J.L., P.D.S., P.S.P., R.C., B.B., S.-Y.Z., A.P., Q.P.-H., Q.Z., and D.N.C. contributed new reagents/analytic tools; P.Z., Q.P., and W.R. analyzed data; and P.Z., D.N.C., L.A., and J.L.-C. wrote the paper.</p>
      </fn>
      <fn id="fn5" fn-type="equal">
        <p><sup>2</sup>Q.P.-H., Q.Z., and D.N.C. contributed equally to this work.</p>
      </fn>
      <fn id="fn6" fn-type="equal">
        <p><sup>3</sup>L.A. and J.-L.C. contributed equally to this work.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="epub">
      <day>28</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>1</day>
      <month>11</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>28</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <volume>119</volume>
    <issue>44</issue>
    <elocation-id>e2211194119</elocation-id>
    <history>
      <date date-type="accepted">
        <day>14</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Copyright © 2022 the Author(s). Published by PNAS.</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This open access article is distributed under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pnas.202211194.pdf"/>
    <abstract abstract-type="executive-summary">
      <title>Significance</title>
      <p>The search for candidate variants underlying human disease in massive parallel sequencing data typically focuses on coding regions and essential splice sites, mostly ignoring noncoding variants. The RNA spliceosome recognizes intronic branchpoint (BP) motifs at the beginning of splicing and operates mostly within introns to define the exon–intron boundaries; however, BP variants have been paid little attention. We established a comprehensive genome-wide database and knowledgebase of BP and developed BPHunter for systematic and informative genome-wide detection of intronic variants that may disrupt BP and splicing, together with an effective strategy for prioritizing BP variant candidates. BPHunter not only constitutes an important resource for understanding BP, but should also drive discovery of BP variants in human genetic diseases and traits.</p>
    </abstract>
    <abstract>
      <p>Pre-messenger RNA splicing is initiated with the recognition of a single-nucleotide intronic branchpoint (BP) within a BP motif by spliceosome elements. Forty-eight rare variants in 43 human genes have been reported to alter splicing and cause disease by disrupting BP. However, until now, no computational approach was available to efficiently detect such variants in massively parallel sequencing data. We established a comprehensive human genome-wide BP database by integrating existing BP data and generating new BP data from RNA sequencing of lariat debranching enzyme DBR1-mutated patients and from machine-learning predictions. We characterized multiple features of BP in major and minor introns and found that BP and BP-2 (two nucleotides upstream of BP) positions exhibit a lower rate of variation in human populations and higher evolutionary conservation than the intronic background, while being comparable to the exonic background. We developed BPHunter as a genome-wide computational approach to systematically and efficiently detect intronic variants that may disrupt BP recognition. BPHunter retrospectively identified 40 of the 48 known pathogenic BP variants, in which we summarized a strategy for prioritizing BP variant candidates. The remaining eight variants all create AG-dinucleotides between the BP and acceptor site, which is the likely reason for missplicing. We demonstrated the practical utility of BPHunter prospectively by using it to identify a novel germline heterozygous BP variant of <italic toggle="yes">STAT2</italic> in a patient with critical COVID-19 pneumonia and a novel somatic intronic 59-nucleotide deletion of <italic toggle="yes">ITPKB</italic> in a lymphoma patient, both of which were validated experimentally. BPHunter is publicly available from <ext-link xlink:href="https://hgidsoft.rockefeller.edu/BPHunter" ext-link-type="uri">https://hgidsoft.rockefeller.edu/BPHunter</ext-link> and <ext-link xlink:href="https://github.com/casanova-lab/BPHunter" ext-link-type="uri">https://github.com/casanova-lab/BPHunter</ext-link>.</p>
    </abstract>
    <kwd-group>
      <kwd>branchpoint</kwd>
      <kwd>splicing</kwd>
      <kwd>intronic variant</kwd>
      <kwd>disease genetics</kwd>
      <kwd>software</kwd>
    </kwd-group>
    <funding-group>
      <award-group award-type="gs1">
        <funding-source id="sp1">Howard Hughes Medical Institute (HHMI) <named-content content-type="funder-id">100000011</named-content></funding-source>
        <award-id rid="sp1">n/a</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs2">
        <funding-source id="sp2">St. Giles Foundation <named-content content-type="funder-id">100002350</named-content></funding-source>
        <award-id rid="sp2">n/a</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs3">
        <funding-source id="sp3">HHS | National Institutes of Health (NIH) <named-content content-type="funder-id">100000002</named-content></funding-source>
        <award-id rid="sp3">R01AI088364</award-id>
        <principal-award-recipient>Shen-Ying Zhang</principal-award-recipient>
        <principal-award-recipient>Qian Zhang</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs4">
        <funding-source id="sp4">HHS | National Institutes of Health (NIH) <named-content content-type="funder-id">100000002</named-content></funding-source>
        <award-id rid="sp4">R01AI163029</award-id>
        <principal-award-recipient>Shen-Ying Zhang</principal-award-recipient>
        <principal-award-recipient>Qian Zhang</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs5">
        <funding-source id="sp5">HHS | NIH | National Center for Advancing Translational Sciences (NCATS) <named-content content-type="funder-id">100006108</named-content></funding-source>
        <award-id rid="sp5">UL1TR001866</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs6">
        <funding-source id="sp6">HHS | NIH | National Human Genome Research Institute (NHGRI) <named-content content-type="funder-id">100000051</named-content></funding-source>
        <award-id rid="sp6">UM1HG006504</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs7">
        <funding-source id="sp7">HHS | NIH | National Human Genome Research Institute (NHGRI) <named-content content-type="funder-id">100000051</named-content></funding-source>
        <award-id rid="sp7">U24HG008956</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs8">
        <funding-source id="sp8">Agence Nationale de la Recherche (ANR) <named-content content-type="funder-id">501100001665</named-content></funding-source>
        <award-id rid="sp8">ANR-10-IAHU-01</award-id>
        <principal-award-recipient>Shen-Ying Zhang</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs9">
        <funding-source id="sp9">Agence Nationale de la Recherche (ANR) <named-content content-type="funder-id">501100001665</named-content></funding-source>
        <award-id rid="sp9">ANR-18-CE15-0020-02</award-id>
        <principal-award-recipient>Shen-Ying Zhang</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs10">
        <funding-source id="sp10">Agence Nationale de la Recherche (ANR) <named-content content-type="funder-id">501100001665</named-content></funding-source>
        <award-id rid="sp10">ANR-20-CO11-0001</award-id>
        <principal-award-recipient>Shen-Ying Zhang</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs11">
        <funding-source id="sp11">Agence Nationale de la Recherche (ANR) <named-content content-type="funder-id">501100001665</named-content></funding-source>
        <award-id rid="sp11">ANR-10-LABX-62-IBEID</award-id>
        <principal-award-recipient>Shen-Ying Zhang</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs12">
        <funding-source id="sp12">Fondation pour la Recherche Médicale (FRM) <named-content content-type="funder-id">501100002915</named-content></funding-source>
        <award-id rid="sp12">EQU201903007798</award-id>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs13">
        <funding-source id="sp13">Fisher Center for Alzheimer's Research Foundation (Fisher Center) <named-content content-type="funder-id">100001621</named-content></funding-source>
        <award-id rid="sp13">n/a</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs14">
        <funding-source id="sp14">Meyer Foundation <named-content content-type="funder-id">100005162</named-content></funding-source>
        <award-id rid="sp14">n/a</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs15">
        <funding-source id="sp15">JPB Foundation (JPBF) <named-content content-type="funder-id">100007457</named-content></funding-source>
        <award-id rid="sp15">n/a</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs16">
        <funding-source id="sp16">Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) <named-content content-type="funder-id">501100003323</named-content></funding-source>
        <award-id rid="sp16">ANRS-COV05</award-id>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs17">
        <funding-source id="sp17">Square Foundation</funding-source>
        <award-id rid="sp17">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs18">
        <funding-source id="sp18">Grandir-Fonds de solidarite pour l&amp;apos;enfance</funding-source>
        <award-id rid="sp18">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs19">
        <funding-source id="sp19">SCOR Corporate Foundation for Science (SCOR Foundation) <named-content content-type="funder-id">100019631</named-content></funding-source>
        <award-id rid="sp19">n/a</award-id>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs20">
        <funding-source id="sp20">Fondation du Souffle (FdS) <named-content content-type="funder-id">100012019</named-content></funding-source>
        <award-id rid="sp20">n/a</award-id>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs21">
        <funding-source id="sp21">Institut National de la Santé et de la Recherche Médicale (Inserm) <named-content content-type="funder-id">501100001677</named-content></funding-source>
        <award-id rid="sp21">n/a</award-id>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs22">
        <funding-source id="sp22">University of Paris Cit&amp;amp;#x00E9;</funding-source>
        <award-id rid="sp22">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs23">
        <funding-source id="sp23">Rockefeller University <named-content content-type="funder-id">100012007</named-content></funding-source>
        <award-id rid="sp23">n/a</award-id>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs24">
        <funding-source id="sp24">Agence Nationale de la Recherche (ANR) <named-content content-type="funder-id">501100001665</named-content></funding-source>
        <award-id rid="sp24">ANR-20-CE93-003</award-id>
        <principal-award-recipient>Shen-Ying Zhang</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
      </award-group>
      <award-group award-type="gs25">
        <funding-source id="sp25">French Ministry of Higher Education, Research, and Innovation</funding-source>
        <award-id rid="sp25">MESRI-COVID-19</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs26">
        <funding-source id="sp26">REACTing-INSERM</funding-source>
        <award-id rid="sp26">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs27">
        <funding-source id="sp27">Cancerfonden (Swedish Cancer Society) <named-content content-type="funder-id">501100002794</named-content></funding-source>
        <award-id rid="sp27">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
      </award-group>
      <award-group award-type="gs28">
        <funding-source id="sp28">Swedish Research Council</funding-source>
        <award-id rid="sp28">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs29">
        <funding-source id="sp29">Radiumhemmets</funding-source>
        <award-id rid="sp29">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
        <principal-award-recipient>Laurent Abel</principal-award-recipient>
        <principal-award-recipient>Jean-Laurent Casanova</principal-award-recipient>
      </award-group>
      <award-group award-type="gs30">
        <funding-source id="sp30">KI | Center for Innovative Medicine (CIMED) <named-content content-type="funder-id">501100018713</named-content></funding-source>
        <award-id rid="sp30">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
      </award-group>
      <award-group award-type="gs31">
        <funding-source id="sp31">Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation) <named-content content-type="funder-id">501100004063</named-content></funding-source>
        <award-id rid="sp31">n/a</award-id>
        <principal-award-recipient>Qiang Pan-Hammarström</principal-award-recipient>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="12"/>
    </counts>
  </article-meta>
</front>
<body>
  <p content-type="flushleft">Pre-mRNA (messenger RNA) splicing is a necessary step for protein-coding gene expression in eukaryotic cells. The biochemical process is initiated by the recognition of the branchpoint (BP) in an intron, followed by the identification and ligation of the 5′ splice site (5′ss = donor site) and 3′ splice site (3′ss = acceptor site) to join two exons and the removal of the intervening intron as a circular lariat, to yield a mature mRNA of coding sequence for protein translation (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">A</italic></xref>). Splicing takes place in the nucleus and is regulated by an array of <italic toggle="yes">cis</italic>-acting elements (the RNA sequences with their splicing codes) and <italic toggle="yes">trans</italic>-acting elements (proteins and small nuclear RNAs (snRNAs) that bind to the <italic toggle="yes">cis</italic>-acting elements), which together constitute a garden around the splice sites promoting the formation of the complex and dynamic spliceosome (<xref rid="r1" ref-type="bibr">1</xref><xref rid="r2" ref-type="bibr"/>–<xref rid="r3" ref-type="bibr">3</xref>). When splicing is initiated, the BP motif is recognized by a spliceosomal snRNA, with the cooperation of splicing factors (<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r5" ref-type="bibr">5</xref>). BP recognition is achieved differently between the two types of spliceosome (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">B</italic></xref>): the major (U2-type, in &gt;99% of human introns) and the minor (U12-type). The main difference between these spliceosomes is the use of different snRNAs. The major spliceosome recruits U1, U2, U4, U5, and U6 snRNAs, in which the U1 and U2 snRNAs recognize 5′ss and BP independently (<xref rid="r1" ref-type="bibr">1</xref>). In the interaction between BP and U2 snRNA, the BP nucleotide bulges out to bind into a pocket formed by SF3B1 and PHF5A (<xref rid="r6" ref-type="bibr">6</xref>), and its flanking sequences base-pair with U2 snRNA (<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r7" ref-type="bibr">7</xref>), while U2 snRNA is stabilized by SF3B6 (<xref rid="r6" ref-type="bibr">6</xref>). The minor spliceosome recruits U11, U12, U4atac, U5, and U6atac snRNAs, in which the U11 and U12 snRNAs first form a di-snRNA complex before recognizing the 5′ss and BP simultaneously (<xref rid="r7" ref-type="bibr">7</xref>, <xref rid="r8" ref-type="bibr">8</xref>).</p>
  <fig position="float" id="fig01" fig-type="featured">
    <label>Fig. 1.</label>
    <caption>
      <p>Schematics of a splicing event, the two types of spliceosome, and typical consequences of a BP variant. (<italic toggle="yes">A</italic>) Schematic of the biological processes of transcription, splicing, and translation from DNA to pre-mRNA to mature mRNA and protein. In pre-mRNA splicing, the BP is first recognized, two exons are then joined, and the intervening intron is finally released as a circular lariat. (<italic toggle="yes">B</italic>) Schematic of the major (U2-type, on the left) and minor (U12-type, on the right) spliceosomes, with an illustration of the interaction between pre-mRNA sequence and U2/U12 snRNA. (<italic toggle="yes">C</italic>) Schematic of the potential molecular consequences of a BP variant, including complete/partial exon skipping and complete/partial intron retention. The percentage in parentheses refer to the observed fraction of each category from the published pathogenic BP variants (note that one variant could result in more than one missplicing consequence).</p>
    </caption>
    <graphic xlink:href="pnas.2211194119fig01" position="float"/>
  </fig>
  <p>BP constitutes a single-nucleotide <italic toggle="yes">cis</italic>-acting element within the intron. It is typically an adenine and generally located [−20, −40] (from −20 to −40) nucleotides (nt) away from the 3′ss. The BP motif is thought to follow the consensus sequence YTN<underline>A</underline>Y (<xref rid="r4" ref-type="bibr">4</xref>) (<underline>A</underline> denotes the BP site, Y = C/T, <italic toggle="yes">n</italic> = any nucleotide). There are also distal BP deeper inside introns: recursive splicing within the intron for multistep intron removal (<xref rid="r9" ref-type="bibr">9</xref>), stem-loop RNA structures bring distal BP closer to 3′ss (<xref rid="r10" ref-type="bibr">10</xref>), stochastic splice site selection leads to kinetic variation in intron removal (<xref rid="r11" ref-type="bibr">11</xref>) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1</ext-link>). So far, considerable efforts have been made to identify BP positions, including a lariat sequencing method to study BP in <italic toggle="yes">Saccharomyces cerevisiae</italic> (<xref rid="r12" ref-type="bibr">12</xref>), a spliceosome profiling method to sequence RNA copurifying with spliceosomal complex in <italic toggle="yes">Schizosaccharomyces pombe</italic> (<xref rid="r13" ref-type="bibr">13</xref>), and analyzing large-scale experimental data in humans [RNA sequencing (RNA-seq) (<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r14" ref-type="bibr">14</xref><xref rid="r15" ref-type="bibr"/><xref rid="r16" ref-type="bibr"/>–<xref rid="r17" ref-type="bibr">17</xref>) and iCLIP (<xref rid="r18" ref-type="bibr">18</xref>)]. To locate BP positions from RNA-seq data, the sequencing reads from the circular lariats that traverse the junctions between 5′ss and BP are identified by aligning to the intronic sequences of 5′ss and 3′ss, respectively. Since lariats are transient and only exist at low abundance, their detection is technically difficult, hence large-scale data are required for identifying BP positions. Spliceosome iCLIP experimentation identifies cross-links of spliceosomal factors on pre-mRNA sequences at nucleotide-level resolution to pinpoint BP positions (<xref rid="r18" ref-type="bibr">18</xref>). Some machine-learning models have also been developed to predict BP positions based on one or two experimentally identified BP datasets (19–21). However, these individual BP studies have yet to be integrated into a comprehensive database and knowledgebase of human BP.</p>
  <p>The functional role of splicing makes it a critical process for the correct assembly of gene products, while its complexity renders it vulnerable to deleterious variants that can perturb any part of the splicing machinery. A variant may affect a <italic toggle="yes">cis</italic>- or <italic toggle="yes">trans</italic>-element, leading to altered splicing with alternative 5′ss/3′ss, exon skipping, or intron retention, any of which could result in the synthesis of a defective gene product (<xref rid="r22" ref-type="bibr">22</xref>, <xref rid="r23" ref-type="bibr">23</xref>). As previously reported (<xref rid="r24" ref-type="bibr">24</xref><xref rid="r25" ref-type="bibr"/>–<xref rid="r26" ref-type="bibr">26</xref>), at least 10% of disease-causing variants are associated with missplicing [of which ∼65% are in essential exonic/intronic splice sites, ∼25% are in the remainder of the intron, and ∼10% are in the remainder of the exon (<xref rid="r25" ref-type="bibr">25</xref>)]; this may, however, be a serious underestimate (<xref rid="r24" ref-type="bibr">24</xref>) owing to our rather limited ability to detect variants that impair different aspects of the spliceosome. Currently, the search for candidate pathogenic variants in massively parallel sequence (MPS) data generally focuses on nonsynonymous variants located within coding sequences or variants in essential splice sites, while mostly ignoring synonymous coding exonic variants and noncoding intronic variants. Data from RNA-seq or other studies of mRNA occasionally lead to the detection of intronic or exonic variants that disrupt splicing (<xref rid="r27" ref-type="bibr">27</xref>). However, the spliceosome operates mostly within intronic regions to define the exon–intron boundaries and hence the coding sequences. It follows that introns probably harbor a substantially larger number of pathogenic variants than has so far been appreciated (<xref rid="r28" ref-type="bibr">28</xref>). The BP, involved in the initiation of splicing through its interactions with spliceosome elements, constitutes a key vulnerability of splicing by virtue of its potential variants.</p>
  <p>Employing the Human Gene Mutation Database (HGMD) Professional version (<xref rid="r25" ref-type="bibr">25</xref>) in concert with an in-depth literature review, we identified 48 BP variants reported in 43 genes underlying 33 human diseases whose pathogenicity has been supported by accompanying experimental evidence. These BP variants resulted in complete/partial exon skipping or intron retention, or a combination of these consequences (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">C</italic></xref>). The misspliced mRNAs may be rapidly degraded by nonsense-mediated decay (NMD), resulting in loss of expression, and the translated truncated proteins could exhibit loss of function, both being potentially disease-causing. However, since the first report of a disease-causing BP variant in the <italic toggle="yes">L1CAM</italic> gene in a family with X-linked hydrocephalus in 1992 (<xref rid="r29" ref-type="bibr">29</xref>), the discovery rate of pathogenic BP variants appears to have been rather low (only 48 variants discovered in the last 30 y). This is probably because 1) genome-wide knowledge of BP has not been systematically integrated and characterized, 2) genome-wide detection software has not been available for the efficient identification of BP variants from MPS data, and 3) in-depth understanding of all reported pathogenic BP variants has not been analyzed, which could potentiate the strategic prioritization of candidate variants that could functionally disrupt BP. We have therefore aimed to fill these gaps both for biological and medical reasons.</p>
  <sec sec-type="results" id="s1">
    <title>Results</title>
    <sec id="s2">
      <title>Collection of Experimentally Identified BP Data.</title>
      <p>We first collated five datasets of experimentally identified BP (eBP), based on RNA-seq and iCLIP data: eBP_Mercer (59,359 BP from total RNA-seq) (<xref rid="r5" ref-type="bibr">5</xref>), eBP_Taggart (27,795 BP from total RNA-seq) (<xref rid="r15" ref-type="bibr">15</xref>), eBP_Pineda (138,313 BP from total RNA-seq) (<xref rid="r16" ref-type="bibr">16</xref>), eBP_Talhouarne (240 BP from cytoplasmic RNA-seq) (<xref rid="r17" ref-type="bibr">17</xref>), and eBP_Briese (43,630 BP from iCLIP) (<xref rid="r18" ref-type="bibr">18</xref>) (<xref rid="t01" ref-type="table">Table 1</xref>). In addition to the published BP datasets, we revisited our RNA-seq data derived from <italic toggle="yes">DBR1</italic>-mutated patients with brainstem viral infection (<xref rid="r30" ref-type="bibr">30</xref>). <italic toggle="yes">DBR1</italic> encodes the only known lariat debranching enzyme, and the patients with <italic toggle="yes">DBR1</italic> variants, who were characterized by a residual DBR1 activity of 3 to 10%, have been reported to exhibit an elevated cellular level of lariats (<xref rid="r30" ref-type="bibr">30</xref>). We designed a computational program to detect BP positions from RNA-seq reads (<xref rid="s20" ref-type="sec"><italic toggle="yes">Methods</italic></xref>), which identified 8,682 BP sites (eBP_BPHunter) from 15 RNA-seq samples from the fibroblasts of three <italic toggle="yes">DBR1</italic>-mutated patients (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2<italic toggle="yes">A</italic> and Table S1</ext-link>). In these six eBP datasets, the most abundant BP nucleotides were eBP_Mercer (79% A), eBP_Taggart (68% A), eBP_Pineda (75% A), eBP_Talhouarne (84% C), eBP_Briese (100% A), and eBP_BPHunter (46% A) (<xref rid="t01" ref-type="table">Table 1</xref>). This showed that adenine-BP were the most frequent in lariats from total RNA-seq, whereas cytosine-BP were the most frequent in the stable lariats in cytoplasm albeit in very low amounts (<xref rid="r17" ref-type="bibr">17</xref>). <italic toggle="yes">DBR1</italic>-mutated patients had 22% stable cytosine-BP. The iCLIP-identified BP were invariably adenine. In total, we obtained 210,986 unique eBP.</p>
      <table-wrap position="float" id="t01">
        <label>Table 1.</label>
        <caption>
          <p>A comprehensive collection of eBP and cBP, including the additional BP data generated in this study (eBP_BPHunter and cBP_BPHunter), followed by consensus-guided positional adjustment</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th rowspan="1" colspan="1">BP dataset</th>
              <th align="center" rowspan="1" colspan="1">No. of raw BP</th>
              <th align="center" rowspan="1" colspan="1">A, %</th>
              <th align="center" rowspan="1" colspan="1">C, %</th>
              <th align="center" rowspan="1" colspan="1">G, %</th>
              <th align="center" rowspan="1" colspan="1">T, %</th>
              <th align="center" rowspan="1" colspan="1">No. of adj. BP</th>
              <th align="center" rowspan="1" colspan="1">A, %</th>
              <th align="center" rowspan="1" colspan="1">C, %</th>
              <th align="center" rowspan="1" colspan="1">G, %</th>
              <th align="center" rowspan="1" colspan="1">T, %</th>
              <th align="center" rowspan="1" colspan="1">Δ no. of BP</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1"> eBP_Mercer</td>
              <td align="char" char="." rowspan="1" colspan="1">59,359</td>
              <td align="char" char="." rowspan="1" colspan="1">78.5</td>
              <td align="char" char="." rowspan="1" colspan="1">8.5</td>
              <td align="char" char="." rowspan="1" colspan="1">4.7</td>
              <td align="char" char="." rowspan="1" colspan="1">8.4</td>
              <td align="right" rowspan="1" colspan="1">54,531</td>
              <td align="char" char="." rowspan="1" colspan="1">84.9</td>
              <td align="char" char="." rowspan="1" colspan="1">8.0</td>
              <td align="char" char="." rowspan="1" colspan="1">3.5</td>
              <td align="char" char="." rowspan="1" colspan="1">3.6</td>
              <td align="right" rowspan="1" colspan="1">−4,828</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> eBP_Taggart</td>
              <td align="char" char="." rowspan="1" colspan="1">27,795</td>
              <td align="char" char="." rowspan="1" colspan="1">67.8</td>
              <td align="char" char="." rowspan="1" colspan="1">15.3</td>
              <td align="char" char="." rowspan="1" colspan="1">5.5</td>
              <td align="char" char="." rowspan="1" colspan="1">11.4</td>
              <td align="right" rowspan="1" colspan="1">27,635</td>
              <td align="char" char="." rowspan="1" colspan="1">73.7</td>
              <td align="char" char="." rowspan="1" colspan="1">13.1</td>
              <td align="char" char="." rowspan="1" colspan="1">4.1</td>
              <td align="char" char="." rowspan="1" colspan="1">9.1</td>
              <td align="right" rowspan="1" colspan="1">−160</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> eBP_Pineda</td>
              <td align="char" char="." rowspan="1" colspan="1">138,313</td>
              <td align="char" char="." rowspan="1" colspan="1">75.0</td>
              <td align="char" char="." rowspan="1" colspan="1">7.6</td>
              <td align="char" char="." rowspan="1" colspan="1">9.5</td>
              <td align="char" char="." rowspan="1" colspan="1">7.9</td>
              <td align="right" rowspan="1" colspan="1">133,652</td>
              <td align="char" char="." rowspan="1" colspan="1">77.0</td>
              <td align="char" char="." rowspan="1" colspan="1">7.3</td>
              <td align="char" char="." rowspan="1" colspan="1">8.9</td>
              <td align="char" char="." rowspan="1" colspan="1">6.9</td>
              <td align="right" rowspan="1" colspan="1">−4,661</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> eBP_Talhouarne</td>
              <td align="char" char="." rowspan="1" colspan="1">240</td>
              <td align="char" char="." rowspan="1" colspan="1">4.6</td>
              <td align="char" char="." rowspan="1" colspan="1">84.2</td>
              <td align="char" char="." rowspan="1" colspan="1">4.6</td>
              <td align="char" char="." rowspan="1" colspan="1">6.7</td>
              <td align="right" rowspan="1" colspan="1">240</td>
              <td align="char" char="." rowspan="1" colspan="1">8.3</td>
              <td align="char" char="." rowspan="1" colspan="1">81.7</td>
              <td align="char" char="." rowspan="1" colspan="1">3.3</td>
              <td align="char" char="." rowspan="1" colspan="1">6.7</td>
              <td align="right" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> eBP_Briese</td>
              <td align="char" char="." rowspan="1" colspan="1">43,630</td>
              <td align="char" char="." rowspan="1" colspan="1">100.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="right" rowspan="1" colspan="1">43,630</td>
              <td align="char" char="." rowspan="1" colspan="1">100.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="right" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> eBP_BPHunter</td>
              <td align="char" char="." rowspan="1" colspan="1">8,682</td>
              <td align="char" char="." rowspan="1" colspan="1">45.9</td>
              <td align="char" char="." rowspan="1" colspan="1">22.4</td>
              <td align="char" char="." rowspan="1" colspan="1">18.2</td>
              <td align="char" char="." rowspan="1" colspan="1">13.5</td>
              <td align="right" rowspan="1" colspan="1">7,990</td>
              <td align="char" char="." rowspan="1" colspan="1">56.6</td>
              <td align="char" char="." rowspan="1" colspan="1">21.8</td>
              <td align="char" char="." rowspan="1" colspan="1">15.7</td>
              <td align="char" char="." rowspan="1" colspan="1">5.8</td>
              <td align="right" rowspan="1" colspan="1">−692</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">eBP</td>
              <td align="char" char="." rowspan="1" colspan="1">210,986</td>
              <td align="char" char="." rowspan="1" colspan="1">73.4</td>
              <td align="char" char="." rowspan="1" colspan="1">9.1</td>
              <td align="char" char="." rowspan="1" colspan="1">8.5</td>
              <td align="char" char="." rowspan="1" colspan="1">9.1</td>
              <td align="right" rowspan="1" colspan="1">198,256</td>
              <td align="char" char="." rowspan="1" colspan="1">76.9</td>
              <td align="char" char="." rowspan="1" colspan="1">8.6</td>
              <td align="char" char="." rowspan="1" colspan="1">7.7</td>
              <td align="char" char="." rowspan="1" colspan="1">6.9</td>
              <td align="right" rowspan="1" colspan="1">−12,730</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> cBP_BPP</td>
              <td align="char" char="." rowspan="1" colspan="1">232,828</td>
              <td align="char" char="." rowspan="1" colspan="1">98.8</td>
              <td align="char" char="." rowspan="1" colspan="1">1.1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.2</td>
              <td align="right" rowspan="1" colspan="1">232,820</td>
              <td align="char" char="." rowspan="1" colspan="1">98.8</td>
              <td align="char" char="." rowspan="1" colspan="1">1.1</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.2</td>
              <td align="right" rowspan="1" colspan="1">−8</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> cBP_Branchpointer</td>
              <td align="char" char="." rowspan="1" colspan="1">352,322</td>
              <td align="char" char="." rowspan="1" colspan="1">98.8</td>
              <td align="char" char="." rowspan="1" colspan="1">0.5</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.7</td>
              <td align="right" rowspan="1" colspan="1">325,304</td>
              <td align="char" char="." rowspan="1" colspan="1">99.5</td>
              <td align="char" char="." rowspan="1" colspan="1">0.6</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="right" rowspan="1" colspan="1">−27,018</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> cBP_LaBranchoR</td>
              <td align="char" char="." rowspan="1" colspan="1">203,914</td>
              <td align="char" char="." rowspan="1" colspan="1">98.3</td>
              <td align="char" char="." rowspan="1" colspan="1">1.6</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="right" rowspan="1" colspan="1">203,907</td>
              <td align="char" char="." rowspan="1" colspan="1">98.3</td>
              <td align="char" char="." rowspan="1" colspan="1">1.6</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="right" rowspan="1" colspan="1">−7</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1"> cBP_BPHunter</td>
              <td align="char" char="." rowspan="1" colspan="1">20,718</td>
              <td align="char" char="." rowspan="1" colspan="1">100.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="right" rowspan="1" colspan="1">20,718</td>
              <td align="char" char="." rowspan="1" colspan="1">100.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="right" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">cBP</td>
              <td align="char" char="." rowspan="1" colspan="1">479,366</td>
              <td align="char" char="." rowspan="1" colspan="1">97.9</td>
              <td align="char" char="." rowspan="1" colspan="1">1.5</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.6</td>
              <td align="right" rowspan="1" colspan="1">451,215</td>
              <td align="char" char="." rowspan="1" colspan="1">98.3</td>
              <td align="char" char="." rowspan="1" colspan="1">1.6</td>
              <td align="char" char="." rowspan="1" colspan="1">0.0</td>
              <td align="char" char="." rowspan="1" colspan="1">0.1</td>
              <td align="right" rowspan="1" colspan="1">−28,151</td>
            </tr>
            <tr>
              <td colspan="6" rowspan="1">Total BP</td>
              <td align="right" rowspan="1" colspan="1">546,559</td>
              <td align="char" char="." rowspan="1" colspan="1">90.40</td>
              <td align="char" char="." rowspan="1" colspan="1">4.25</td>
              <td align="char" char="." rowspan="1" colspan="1">2.78</td>
              <td align="char" char="." rowspan="1" colspan="1">2.57</td>
              <td align="right" rowspan="2" colspan="1"/>
            </tr>
            <tr>
              <td colspan="6" rowspan="1">mBP</td>
              <td align="right" rowspan="1" colspan="1">102,912</td>
              <td align="char" char="." rowspan="1" colspan="1">99.15</td>
              <td align="char" char="." rowspan="1" colspan="1">0.83</td>
              <td align="char" char="." rowspan="1" colspan="1">0.01</td>
              <td align="char" char="." rowspan="1" colspan="1">0.01</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="s3">
      <title>Collection of Computationally Predicted BP Data.</title>
      <p>We also collated three datasets of computationally predicted BP (cBP): cBP_BPP (232,828 BP) (<xref rid="r19" ref-type="bibr">19</xref>), cBP_Branchpointer (352,322 BP) (<xref rid="r20" ref-type="bibr">20</xref>), and cBP_LaBranchoR (203,914 BP) (<xref rid="r21" ref-type="bibr">21</xref>) (<xref rid="t01" ref-type="table">Table 1</xref>). These studies trained machine-learning models based on one/two eBP datasets and performed predictions in the region [−21, −34], [−18, −44] and [−1, −70] nt of 3′ss respectively. These cBP datasets supplemented the BP positions that were not detected from experimental data and hence increased the BP coverage across the human genome. These computational methods overlapped the predictions in [−21, −34] nt of 3′ss, with less attention being paid to in the region closer to 3′ss, which is generally considered to comprise polypyrimidine tracts (PPT). However, the use of a hard distance cutoff for PPT or the use of an algorithm to estimate PPT to skip BP prediction could miss potentially genuine BP sites. For this reason, we postulated that there could be additional BP candidates in the region closer to 3′ss. Therefore, we developed a high-precision machine-learning model: a set of three algorithms (gradient boost machine, random forest, and logistic regression) that are tuned for high precision and integrated with majority voting for the final prediction (<xref rid="s20" ref-type="sec"><italic toggle="yes">Methods</italic></xref>). These three models were independently trained on the 198,256 consensus-guided position-adjusted eBP positions (discussed in the next section; <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></ext-link>) versus 1 million random intronic/exonic positions and then optimized by tuning parameters and thresholds through cross-validation (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2<italic toggle="yes">D</italic></ext-link>). We used the model to predict BP in [−3, −40] nt of 3′ss, and it yielded 20,718 BP sites (cBP_BPHunter). In these four cBP datasets, the most abundant BP nucleotides were cBP_BPP (99% A), cBP_Branchpointer (99% A), cBP_LaBranchoR (98% A), and cBP_BPHunter (100% A) (<xref rid="t01" ref-type="table">Table 1</xref>), showing that the prediction models favored adenine-BP. In total, we obtained 479,366 unique cBP. Please note that cBP does not denote cytosine-BP. When we mention the nucleotides of BP, we fully spell out the nucleotide (e.g., adenine-BP, cytosine-BP).</p>
    </sec>
    <sec id="s4">
      <title>Consensus-Guided Positional Adjustment of BP and Integration of BP Datasets.</title>
      <p>We tested the established BP consensus sequence YTNAY (<xref rid="r4" ref-type="bibr">4</xref>) in eBP but found only 23.5% eBP matched this pattern precisely. Considering the noncanonical 2′-to-5′ linkage between 5′ss and BP, and the possibility of mutations being introduced by reverse transcriptase when traversing the 5′ss-BP junction in RNA-seq (<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r15" ref-type="bibr">15</xref>), we anticipated that a number of eBP may have been mislocated in the raw dataset (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2<italic toggle="yes">B</italic></ext-link>), which could also have led to some mislocated cBP predictions. We therefore screened a window of [−2, +2] nt from each BP position for consensus sequence matching and adjusted the raw BP position to its closest neighbor that perfectly matched YTNAY (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S2<italic toggle="yes">C</italic></ext-link>). As a result, about 6% of raw BP positions were adjusted (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S2</ext-link>), and multiple neighboring raw BP positions were merged into a single adjusted position, yielding 198,256 eBP (Δ = −12,730) and 451,215 cBP (Δ = −28,151) after adjustment (<xref rid="t01" ref-type="table">Table 1</xref>). By integrating eBP and cBP, we assembled a comprehensive collection of 546,559 BP in the human genome, with 102,912 mutually shared BP (mBP) (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">A</italic></xref>, <xref rid="t01" ref-type="table">Table 1</xref><ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">, SI Appendix</italic>, Fig. S3 and Table S3</ext-link>, and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S1</ext-link>). This BP database contained 90.4% adenine-BP, 4.25% cytosine-BP, 2.78% guanine-BP, and 2.57% thymine-BP. We further decomposed adenine-BP by adopting increasingly relaxed consensus sequences: YTNAY (35.8%), YTNA (53.65%), TNA (74.32%), and YNA (77.24%) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S4</ext-link>). We then examined the region [−50, +20] nt of BP for motif enrichment and reported 14 enriched motifs (<italic toggle="yes">P</italic> &lt; 0.05, occurrence &gt;5%) in the 50-nt upstream region of BP, which could represent <italic toggle="yes">cis</italic>-acting elements with a role in facilitating splicing (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S5</ext-link>).</p>
      <fig position="float" id="fig02" fig-type="figure">
        <label>Fig. 2.</label>
        <caption>
          <p>Integration of all BP datasets and mapping of BP onto introns. (<italic toggle="yes">A</italic>) The nucleotide composition displays the motif [−9, +3] of BP, where the locations of BP are marked with a red background. (<italic toggle="yes">B</italic>) BP were mapped to 3′-proximal intron. (<italic toggle="yes">C</italic>) Distance from the mapped BP to their corresponding 3′ss. (<italic toggle="yes">D</italic>) The number of BP mapped to each 3′-proximal intron.</p>
        </caption>
        <graphic xlink:href="pnas.2211194119fig02" position="float"/>
      </fig>
    </sec>
    <sec id="s5">
      <title>Mapping BP to Introns.</title>
      <p>We identified 200,059 unique introns from 41,975 transcripts of 17,372 protein-coding genes and classified introns into 199,393 (99.7%) major and 666 (0.3%) minor types (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S6</ext-link> and <xref rid="s20" ref-type="sec"><italic toggle="yes">Methods</italic></xref>). Because the major and minor spliceosomes regulate splicing differently (<xref rid="r7" ref-type="bibr">7</xref>) (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">B</italic></xref>), it is important to distinguish intron types when studying BP and splicing. Major introns were dominated by GT-AG (98.9%) as the 5′ss–3′ss terminal dinucleotides, whereas 71% and 24% of minor introns were GT-AG and AT-AC, respectively. We mapped 546,559 BP onto 200,059 introns, retained the BP within [−3, −100] nt of 3′ss (3′-proximal introns), and finally obtained 386,209 BP associated with 200,059 introns (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">B</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Datasets S2 and S3</ext-link>). We excluded the distal BP in this study, as more complicated splicing mechanisms may occur (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S1</ext-link>). Among the intron-associated BP, 57% of them were located within a 10-nt window [−21, −30] nt of 3′ss, and 88% were located within a 25-nt window [−15, −40] nt of 3′ss (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">C</italic></xref>); 32%, 41%, and 18% of 3′-proximal introns had one, two, and three BP mapped, respectively, while 9% of 3′-proximal introns harbored more than three BP (<xref rid="fig02" ref-type="fig">Fig. 2<italic toggle="yes">D</italic></xref>). With 68% of 3′-proximal introns containing multiple BP, we found that these BP were largely located in proximity. By taking the first BP in each intron as the reference (i.e., the one closest to the 3′ss), 31% and 59% of nonfirst BP were found to be located within 5 nt and 10 nt upstream of the first BP (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S7</ext-link>). With multiple BP, the first BP could be the most important, as one study showed that BP closer to 3′ss were much more likely to influence splicing efficiency (<xref rid="r31" ref-type="bibr">31</xref>). The BP usage is also expected to be context-specific in alternatively spliced transcripts, but we do not have the requisite data to differentiate the usage. Thus, in this study, we considered the BP–intron associations in a general setting.</p>
    </sec>
    <sec id="s6">
      <title>Nucleotide Composition, BP-3′ss Distance, and BP-U2/U12 snRNA Binding Energy in Major and Minor Introns.</title>
      <p>In major introns, BP motifs exhibited high conservation of A (92%) at pos:0 and T (72%) at pos:−2 and high pyrimidine content (C/T) at pos:−2 (84%), pos: −3 (69%), and pos:+1 (66%). In minor introns, BP showed high conservation of A (95%) at pos:0 and T (78%) at pos: −2 and high pyrimidine content at pos:[−2, −5] and pos:+1 with frequencies 89%, 75%, 67%, 66%, and 67%, respectively (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">A</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S4</ext-link>). We found 2% and 67% of BP in major introns were distributed in regions [−3, −15] and [−16, −30] nt of 3′ss, whereas 27% and 43% of BP in minor introns were found within these two regions (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">B</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S5</ext-link>). BP in minor introns were generally located closer to 3′ss than BP in major introns, which is consistent with the major spliceosome requiring the binding of U2AF65 with PPT that needs a larger spacing, which is absent in the minor spliceosome (<xref rid="r7" ref-type="bibr">7</xref>). We further estimated the binding energy between BP and snRNA and found that BP in major introns displayed weaker binding with U2-snRNA than that between BP and U12-snRNA in minor introns (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">C</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S5</ext-link>). This may imply that the BP–U2 interaction in the major spliceosome can be complemented by other spliceosomal elements (e.g., SF3B1, SF3B6, PHF5A, SFA2, SFA3) (<xref rid="r6" ref-type="bibr">6</xref>), and hence a weaker wobble BP–U2 base pairing could be acceptable. Since the minor spliceosome forms a U11–U12 di-snRNA complex to bind to 5′ss and BP simultaneously, it requires more perfect BP–U12 base pairing, which is also reflected in more conserved 5′ss and BP motifs in minor introns (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">A</italic></xref>).</p>
      <fig position="float" id="fig03" fig-type="figure">
        <label>Fig. 3.</label>
        <caption>
          <p>Characterization of BP. (<italic toggle="yes">A</italic>) Nucleotide composition of BP, 5′ss, and 3′ss motifs in major and minor introns. (<italic toggle="yes">B</italic>) The distance from BP to 3′ss in major and minor introns. (<italic toggle="yes">C</italic>) The binding energy between BP motif and U2/U12 snRNA in major and minor introns (the lower the energy, the higher the binding affinity). (<italic toggle="yes">D</italic>) The proportion of each genomic position harboring population variants (<italic toggle="yes">Upper</italic>), and the MAF distribution of population variants (<italic toggle="yes">Lower</italic>). (<italic toggle="yes">E</italic>) The distribution of the conservation scores GERP (<italic toggle="yes">Left</italic>) and PhyloP (<italic toggle="yes">Right</italic>) in each genomic position. (<italic toggle="yes">F</italic>) The cross-compared conservation scores between BP and BP−2 positions.</p>
        </caption>
        <graphic xlink:href="pnas.2211194119fig03" position="float"/>
      </fig>
    </sec>
    <sec id="s7">
      <title>Population Variants in BP.</title>
      <p>We obtained human population variants from the gnomAD database r3.1.1 (<xref rid="r32" ref-type="bibr">32</xref>), with which to compare the occurrence of population variants in the BP region, essential/flanking splice sites, and intronic/exonic background. We focused on the [−3, +1] positions of 386,209 BP, took a 4-nt window for each splice site ([−1, +3] of 5′ss and [−3, +1] of 3′ss) from 200,059 introns and randomly sampled 1 million positions from the intron and exon backgrounds. In this way, we generated 15 sets of genomic locations for comparison with their population variants (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">D</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S6</ext-link>). We found that 17.4% of intronic and 16% of exonic background positions harbored population variants; 13.9 to 15.1% of the flanking splice sites had population variants, whereas the essential splice sites exhibited a much lower proportion (6.4 to 10.7%). Among the BP regions, 14.5% of BP positions, 15.4% of BP−1 positions, and 12.7% of BP−2 positions harbored population variants, which were lower than those for the intron and exon backgrounds and similar to the flanking positions of splice sites. The other two positions in the BP region (BP−3 and BP+1) had 17.1% and 18.7% of population variants respectively, which were close to or even higher than the intronic background. The minor allele frequencies (MAF) of these population variants at each position also suggested a similar pattern (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">D</italic></xref>). An extended window around splice sites ([−2, +5] of 5′ss and [−5, +2] of 3′ss) is shown in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S8</ext-link>. These findings suggested that the BP and BP−2 positions exhibit a lower rate and a lower frequency of population variations than the intronic background and are similar to the exonic background and flanking positions of essential splice sites.</p>
    </sec>
    <sec id="s8">
      <title>Cross-Species Conservation of BP.</title>
      <p>We evaluated genome-wide conservation scores, GERP (<xref rid="r33" ref-type="bibr">33</xref>) and PhyloP (<xref rid="r34" ref-type="bibr">34</xref>), in the abovementioned 15 sets of genomic locations. A positive score denotes that the position is likely to be evolutionarily conserved, whereas a negative score indicates that the position is probably evolving neutrally (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">E</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S7</ext-link>). Both scores were found to be comparable for each position studied. The essential splice sites and their exonic flanking regions displayed an absolute positive distribution of conservation scores, whereas their intronic flanking sites exhibited a reduced level of conservation. Intronic positions were mostly around zero, whereas exonic positions were mostly positive. The BP region displayed a larger proportion of positive scores (evolutionarily conserved) than negative scores (evolving neutrally), with two peaks of high PhyloP scores at BP and BP−2 positions. We cross-compared the scores between BP and BP−2 (<xref rid="fig03" ref-type="fig">Fig. 3<italic toggle="yes">F</italic></xref>) and found that ∼23% of negatively scored BP positions had positive scores for their corresponding BP−2 positions (second quadrant), while ∼22% of negatively scored BP−2 positions had positive scores for their corresponding BP positions (fourth quadrant). Thus, if we consider at least one positive score for BP or BP−2 position, 86% of BP regions were evolutionarily conserved. Taken together, these findings suggested that the BP region is more highly conserved than the intronic background but less conserved than the exonic background and splice sites. It may also hint at a possible collaborative role between BP and BP−2 to ensure a certain level of conservation. An extended window around splice sites is shown in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S9</ext-link>. A recent study of the bovine genome showed that bovine BP are under evolutionary constraint (<xref rid="r35" ref-type="bibr">35</xref>). It is worth noting that splicing evolves rapidly between species (<xref rid="r36" ref-type="bibr">36</xref>), with one study showing significant splicing differences between primates, including human and chimpanzee (<xref rid="r37" ref-type="bibr">37</xref>). This suggests that the conservation scores of splicing regulatory elements may not be invariably correlated with their functional importance. In other words, BP with low/negative conservation scores could be functionally important.</p>
    </sec>
    <sec id="s9">
      <title>Comparative Characterization of BP.</title>
      <p>We made seven comparisons of BP in the major introns, at intron, transcript, gene, and chromosome levels: 1) 353,031 adenine-BP vs. 14,476 cytosine-BP vs. 9,626 guanine-BP vs. 7,381 thymine-BP (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S10</ext-link>). We found that adenine-/thymine-BP had much lower rates of population variation than cytosine-/guanine-BP, and they had two spikes of high PhyloP conservation scores. 2) 94,581 mBP vs. 60,450 exclusively eBP vs. 229,483 exclusively cBP (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S11</ext-link>). mBP displayed the most conserved nucleotide composition, the lowest rate of population variation, and the largest proportion of positive conservation scores, followed by exclusively cBP and then exclusively eBP. 3) 180,766 first BP vs. 203,748 nonfirst BP (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S12</ext-link>) had no distinct feature noted. 4) 57,254 BP in 3′-proximal introns with single BP vs. 327,260 BP in 3′-proximal introns with multiple BP (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S13</ext-link>). BP in introns of single BP showed an absolute dominance (96%) of T in the BP−2 position, a lower rate of population variation, and a larger proportion of positive conservation scores. 5) 335,617 BP in introns without alternative splicing vs. 48,897 BP in introns with alternative splicing (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S14</ext-link>) had no notable difference. 6) 148,571 BP in genes encoding a single isoform vs. 235,943 BP in genes encoding multiple isoforms (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S15</ext-link>) had no notable difference. 7) 13,876 BP in genes located on the sex (X and Y) chromosomes vs. 370,638 BP in genes located on the autosomes (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S16</ext-link>). The sex chromosomes had a slightly higher proportion of 3′-proximal introns with single BP (36% vs. 31%) than the autosomes. We found that 8.7% of BP on sex chromosomes and 15% of BP on autosomes harbored population variants, revealing a lower rate of population variation of BP on sex chromosomes than autosomes. This may be due to the three population copies of X chromosomes (two copies in females, but one copy in males) compared to four population copies of autosomes (two copies in both females and males) and some other factors (e.g., effective population size, demography) (<xref rid="r38" ref-type="bibr">38</xref>).</p>
    </sec>
    <sec id="s10">
      <title>Pathogenic BP Variants.</title>
      <p>Variants in BP may lead to reduced, altered, or abolished binding to spliceosome elements during the initiation of splicing, leading to the disruption of splicing and giving rise to misspliced gene products with the consequent loss of expression/function (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">C</italic></xref>). Through the HGMD database and primary literature, we identified 48 pathogenic BP variants (42 single-nucleotide variants [SNVs] and 6 microdeletions) reported in 43 human genes underlying 33 different disorders that had been experimentally confirmed (<xref rid="t02" ref-type="table">Table 2</xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S8</ext-link>), from the first report of a BP variant in the <italic toggle="yes">L1CAM</italic> gene causing X-linked hydrocephalus in 1992 (<xref rid="r29" ref-type="bibr">29</xref>) to a recent study of BP variants in hereditary cancer genes in 2021 (<xref rid="r39" ref-type="bibr">39</xref>). These disorders were attributed to different classes of disease: developmental, oncogenic, metabolic, neurological, immunological, and circulatory. These BP variants comprised 16 homozygotes, 23 heterozygotes, 6 hemizygotes, and 3 without zygosity information and were located within [−9, −40] nt of 3′ss. Taking the reported missplicing consequences together (one variant may have multiple missplicing consequences), we identified 29 (60%) complete and 7 (15%) partial exon skippings and 10 (21%) complete and 11 (23%) partial intron retentions, suggesting that complete exon skipping may be the predominant molecular consequence from the disruption of BP recognition. The discovery narrative of these pathogenic BP variants generally occurred in a similar context (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Box S1</ext-link>). Their discovery timeline showed that 11, 15, and 22 pathogenic BP variants were published in the 1990s, the 2000s, and since 2010, respectively. Thus, neither the advent of MPS technology (since 2010) nor the publication of large-scale human BP datasets (since 2015) has resulted in a major increase in the identification of pathogenic BP variants. In fact, paradoxically, the proportion of pathogenic BP variants among all pathogenic variants discovered since the 1990s has steadily decreased. The detection efficiency of pathogenic BP variants is rather low when compared with other types of variant. Therefore, there is an urgent need to bridge BP data with MPS data, thereby extending the utility of the MPS data, making more practical use of the BP data and contributing to pathogenetic discovery.</p>
      <table-wrap position="float" id="t02">
        <label>Table 2.</label>
        <caption>
          <p>The 48 reported pathogenic BP variants underlying human inherited disorders, with experimentally confirmed molecular consequences</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="center" colspan="5" rowspan="1">Pathogenic BP variants</th>
              <th align="center" colspan="2" rowspan="1">BPHunter detection</th>
            </tr>
            <tr>
              <th rowspan="1" colspan="1">Gene</th>
              <th align="center" rowspan="1" colspan="1">Variant</th>
              <th align="center" rowspan="1" colspan="1">Distance to 3′ss</th>
              <th align="center" rowspan="1" colspan="1">Disease</th>
              <th align="center" rowspan="1" colspan="1">Consequence</th>
              <th align="center" rowspan="1" colspan="1">Rank</th>
              <th align="center" rowspan="1" colspan="1">Hit position</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">ABCC8</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.17452526T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−20</td>
              <td rowspan="1" colspan="1">Hyperinsulinemic hypoglycemia</td>
              <td rowspan="1" colspan="1">Partial retention of intron-11 (73nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">ALPL</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.21896765_21896784del</td>
              <td align="center" rowspan="1" colspan="1">−33</td>
              <td rowspan="1" colspan="1">Hypophosphatasia</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-8 and exon-7/8</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2|−1|0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">BBS1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.66287067A &gt; T</td>
              <td align="center" rowspan="1" colspan="1">−21</td>
              <td rowspan="1" colspan="1">Retinitis pigmentosa</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-8 and exon-7/8, partial skipping of exon-8 (30 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">BTK</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.100609705T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−23</td>
              <td rowspan="1" colspan="1">Agammaglobulinemia</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-16</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">C21orf2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.45750232T &gt; A</td>
              <td align="center" rowspan="1" colspan="1">−23</td>
              <td rowspan="1" colspan="1">Axial spondylometaphyseal dysplasia</td>
              <td rowspan="1" colspan="1">Complete retention of intron-6</td>
              <td align="center" rowspan="1" colspan="1">#2/3</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">CAPN3</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.42684808del</td>
              <td align="center" rowspan="1" colspan="1">−29</td>
              <td rowspan="1" colspan="1">Calpainopathy</td>
              <td rowspan="1" colspan="1">Partial retention of intron-6 (389 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">CD40LG</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.135736500_135736507del</td>
              <td align="center" rowspan="1" colspan="1">−32</td>
              <td rowspan="1" colspan="1">X-linked hyper-IgM syndrome</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-3</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2|−1|0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">CDT1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.88873665A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−24</td>
              <td rowspan="1" colspan="1">Meier-Gorlin syndrome</td>
              <td rowspan="1" colspan="1">Complete retention of intron-8, complete skipping of exon-9</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">COL4A5</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.107849932A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−40</td>
              <td rowspan="1" colspan="1">Alport syndrome</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-29, partial skipping of exon-29 (43 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">COL5A1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.137686903T &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−25</td>
              <td rowspan="1" colspan="1">Ehlers-Danlos syndrome type II</td>
              <td rowspan="1" colspan="1">Partial skipping of exon-33 (45 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">COL7A1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.48616971T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−23</td>
              <td rowspan="1" colspan="1">Dystrophic epidermolysis bullosa</td>
              <td rowspan="1" colspan="1">Complete retention of intron-58 and intron-58/59, complete skipping of exon-59</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">CPS1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.211452758A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−24</td>
              <td rowspan="1" colspan="1">Hyperammonemia</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-7</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">DYSF</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.71817308A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−33</td>
              <td rowspan="1" colspan="1">Limb-girdle muscular dystrophy</td>
              <td rowspan="1" colspan="1">Complete retention of intron-31</td>
              <td align="center" rowspan="1" colspan="1">#2/2</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">ENG</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.130578354A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−22</td>
              <td rowspan="1" colspan="1">Pulmonary arterial hypertension</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-13</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">F8</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.154130469T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−27</td>
              <td rowspan="1" colspan="1">Hemophilia A</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-19</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">F9</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.138619496A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−25</td>
              <td rowspan="1" colspan="1">Hemophilia B</td>
              <td rowspan="1" colspan="1">Partial retention of intron-2 (25 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">FAS</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.90770494A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−16</td>
              <td rowspan="1" colspan="1">Autoimmune lymphoproliferative syndrome</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-6</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">FBN2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.127670562A &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−26</td>
              <td rowspan="1" colspan="1">Congenital contractural arachnodactyly</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-31</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">FBN2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.127671284T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−15</td>
              <td rowspan="1" colspan="1">Congenital contractural arachnodactyly</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-29</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">FGD1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.54476769del</td>
              <td align="center" rowspan="1" colspan="1">−35</td>
              <td rowspan="1" colspan="1">Aarskog–Scott syndrome</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-13</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">HEXB</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.74014605A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−17</td>
              <td rowspan="1" colspan="1">Sandhoff disease</td>
              <td rowspan="1" colspan="1">Partial retention of intron-10 (37nt)</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">IKBKG</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.153788599A &gt; T</td>
              <td align="center" rowspan="1" colspan="1">−23</td>
              <td rowspan="1" colspan="1">Ectodermal dysplasia with primary immunodeficiencies</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-5 and exon-3/4/5/6, complete retention of intron-4</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">ITGB2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.46321660A &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−12</td>
              <td rowspan="1" colspan="1">Leukocyte adhesion deficiency</td>
              <td rowspan="1" colspan="1">Partial skipping of exon-6 (149 nt)</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">ITGB4</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.73732344T &gt; A</td>
              <td align="center" rowspan="1" colspan="1">−25</td>
              <td rowspan="1" colspan="1">Epidermolysis bullosa with pyloric atresia</td>
              <td rowspan="1" colspan="1">Complete retention of intron-14 and intron-14/15</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">ITGB4</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.73748508T &gt; A</td>
              <td align="center" rowspan="1" colspan="1">−19</td>
              <td rowspan="1" colspan="1">Epidermolysis bullosa with pyloric atresia</td>
              <td rowspan="1" colspan="1">Complete retention of intron-31, partial skipping of exon-32 (38 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">KCNH2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.150646165T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−28</td>
              <td rowspan="1" colspan="1">Long QT syndrome</td>
              <td rowspan="1" colspan="1">Partial retention of intron-9 (147 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">L1CAM</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.153131293T &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−19</td>
              <td rowspan="1" colspan="1">X-linked hydrocephalus</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-19, partial retention of intron-18 (69 nt)</td>
              <td align="center" rowspan="1" colspan="1">#2/3</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">LCAT</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.67976512A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−22</td>
              <td rowspan="1" colspan="1">Fish-eye disease</td>
              <td rowspan="1" colspan="1">Complete retention of intron-4</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">LIPC</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.58830518A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−14</td>
              <td rowspan="1" colspan="1">Hypertriglyceridemia and cardiovascular disease</td>
              <td rowspan="1" colspan="1">Complete retention of intron-1, partial retention of intron-1 (13 nt, 78 nt)</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">LMX1B</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.129377625_129377641del</td>
              <td align="center" rowspan="1" colspan="1">−37</td>
              <td rowspan="1" colspan="1">Nail patella syndrome</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-2</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2|−1|0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">MLH1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.37090369T &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−26</td>
              <td rowspan="1" colspan="1">Inherited cancer</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-17</td>
              <td align="center" rowspan="1" colspan="1">#2/3</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">MLH1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.37090371A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−24</td>
              <td rowspan="1" colspan="1">Inherited cancer</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-17</td>
              <td align="center" rowspan="1" colspan="1">#2/3</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">MSH2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.47709894A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−24</td>
              <td rowspan="1" colspan="1">Inherited cancer</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-16 and 3′ untranslated region, partial retention of intron-15 (85 nt, 141 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">MSH6</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.48032731T &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−26</td>
              <td rowspan="1" colspan="1">Inherited cancer</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-5</td>
              <td align="center" rowspan="1" colspan="1">#2/3</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">NPC1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.21137182T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−28</td>
              <td rowspan="1" colspan="1">Niemann-Pick type C disease</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-7</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">NTRK1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.156843392T &gt; A</td>
              <td align="center" rowspan="1" colspan="1">−33</td>
              <td rowspan="1" colspan="1">Congenital insensitivity to pain with anhidrosis</td>
              <td rowspan="1" colspan="1">Partial retention of intron-7 (137nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">RB1</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.49039315A &gt; T</td>
              <td align="center" rowspan="1" colspan="1">−26</td>
              <td rowspan="1" colspan="1">Retinoblastoma</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-24</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">−1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">SLC25A20</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.48921567A &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−10</td>
              <td rowspan="1" colspan="1">Carnitineacylcarnitine translocase deficiency</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-3 and exon-3/4</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">SLC5A2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.31499327_31499349del</td>
              <td align="center" rowspan="1" colspan="1">−31</td>
              <td rowspan="1" colspan="1">Familial renal glycosuria</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-8</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">−2|−1|0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">TH</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.2187017A &gt; T</td>
              <td align="center" rowspan="1" colspan="1">−24</td>
              <td rowspan="1" colspan="1">Extrapyramidal movement disorder</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-12, partial retention of intron-11 (36 nt)</td>
              <td align="center" rowspan="1" colspan="1">#3/3</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">TSC2</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.2138031A &gt; G</td>
              <td align="center" rowspan="1" colspan="1">−18</td>
              <td rowspan="1" colspan="1">Tuberous sclerosis</td>
              <td rowspan="1" colspan="1">Complete retention of intron-38, partial skipping of exon-39 (74 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">UROS</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.127477605A &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−31</td>
              <td rowspan="1" colspan="1">Congenital erythropoietic porphyria</td>
              <td rowspan="1" colspan="1">Partial retention of intron-9 (81 nt, 246 nt, 358 nt, 523 nt)</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">−2</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">USH2A</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.216040529T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−17</td>
              <td rowspan="1" colspan="1">Usher syndrome</td>
              <td rowspan="1" colspan="1">Partial skipping of exon-44 (39 nt)</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">VMA21</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.150572076A &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−27</td>
              <td rowspan="1" colspan="1">Autophagic vacuolar myopathy</td>
              <td rowspan="1" colspan="1">Showed significant reduction of expression and activity</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">VMA21</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.150572076A &gt; T</td>
              <td align="center" rowspan="1" colspan="1">−27</td>
              <td rowspan="1" colspan="1">Autophagic vacuolar myopathy</td>
              <td rowspan="1" colspan="1">Showed significant reduction of expression and activity</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">VWF</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.6101204T &gt; A</td>
              <td align="center" rowspan="1" colspan="1">−20</td>
              <td rowspan="1" colspan="1">von Willebrand disease</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-38</td>
              <td align="center" rowspan="1" colspan="1">#1/2</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">XPC</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.14209889A &gt; T</td>
              <td align="center" rowspan="1" colspan="1">−9</td>
              <td rowspan="1" colspan="1">Xeroderma pigmentosum</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-4</td>
              <td align="center" colspan="2" rowspan="1">N.D.</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <italic toggle="yes">XPC</italic>
              </td>
              <td align="center" rowspan="1" colspan="1">g.14209904T &gt; C</td>
              <td align="center" rowspan="1" colspan="1">−24</td>
              <td rowspan="1" colspan="1">Xeroderma pigmentosum</td>
              <td rowspan="1" colspan="1">Complete skipping of exon-4</td>
              <td align="center" rowspan="1" colspan="1">#1/1</td>
              <td align="center" rowspan="1" colspan="1">0</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn>
            <p>All references are available in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S8</ext-link>. Full information on these variants with BPHunter’s annotations are available in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S4</ext-link>. (The genomic positions are on the hg19/GRCh37 human genome assembly. Hit position: BP positions disrupted by the variant. N.D.: not detected.)</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="s11">
      <title>BPHunter: Detection of Intronic Variants That Disrupt the BP.</title>
      <p>Variants that affect BP recognition may be individually rare, but their impact on splicing, gene expression, and protein function can be highly deleterious. Therefore, in searching for disease-causing variants, we should routinely consider BP variants as a discrete category of potentially damaging variants, especially when the search within coding regions and essential splice sites has turned out to be unproductive. We therefore developed BPHunter for the genome-wide detection of human intronic variants that disrupt the BP in MPS data, thereby enabling the identification of BP variant candidates that could potentially result in aberrant splicing at a biochemical level and hence disease at a physiological level. Given a VCF file of variants, BPHunter detects those variants that disrupt BP with informative outputs (<xref rid="BOX1" ref-type="boxed-text">Box 1</xref>). We developed the BPHunter as a one-line command that can be easily implemented into MPS analysis and also as a user-friendly webserver for users with less computational expertise. We believe that there may have been many negative findings involving BP variants that were tested but never reported. To improve our understanding of functional BP, their mutational consequences, their utilization of alternative BP, and their cell-type specificity, we ought to respect the potential value to be derived from these negative data. Therefore, we created a reporting platform in the BPHunter webserver for researchers to submit their tested BP variants that do not display aberrant splicing. These data will be periodically collated and analyzed, and the report will become available on our website and as a preprint, with all contributing researchers acknowledged as members of the BPHunter Effort Group. As we cannot validate the submitted negative BP variants centrally, we shall require all investigators to take responsibility for their submitted data. Therefore, BPHunter constitutes a computational method capable of detecting candidate BP-disrupting variants and a platform for collating the negative results from BP genetics studies that should not be wasted.</p>
      <boxed-text id="BOX1" position="float">
        <sec>
          <title>Box 1: Input and Output of BPHunter</title>
          <p>BPHunter supports both hg19/GRCh37 and hg38/GRCh38 human reference genomes and provides an option to focus on all or canonical transcripts. Given a VCF file of variants with the first five columns as mandatory fields (CHROM, POS, ID, REF, ALT), BPHunter outputs a text file of the variants that disrupt [−2, 0] nt region of BP, with the following informative annotations:<list list-type="simple"><list-item><label>•</label><p>variant type (snv, x nt-deletion, x nt-insertion)</p></list-item><list-item><label>•</label><p>gene symbol</p></list-item><list-item><label>•</label><p>BP name (m/e/cBP_chrom_pos_strand_nucleotide)</p></list-item><list-item><label>•</label><p>BP ranking in this 3′-proximal intron (#rank/total)</p></list-item><list-item><label>•</label><p>BP position hit (−2, −1, 0)</p></list-item><list-item><label>•</label><p>distance from BP to 3′ss</p></list-item><list-item><label>•</label><p>level of consensus (1:YTNAY, 2:YTNA, 3:TNA, 4:YNA, 0:none)</p></list-item><list-item><label>•</label><p>number of sources, and list of sources</p></list-item><list-item><label>•</label><p>population variant MAF at BP and BP-2 positions (noted as “.” if no variant found)</p></list-item><list-item><label>•</label><p>conservation scores GERP and PhyloP at BP and BP−2 positions</p></list-item><list-item><label>•</label><p>intron type (major, minor), and intron length</p></list-item><list-item><label>•</label><p>transcript ID and intron number (e.g., ENST123456789_IVS10)</p></list-item><list-item><label>•</label><p>BPHunter score (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S20</ext-link>)</p></list-item></list></p>
          <p>In addition, the BPHunter webserver provides a negative BP reporting platform, which requires the submitters to provide variant information, cell type, assay type, and experimental evidence following the template (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S6</ext-link>).</p>
        </sec>
      </boxed-text>
    </sec>
    <sec id="s12">
      <title>Validation of BPHunter on the Reported Pathogenic BP Variants.</title>
      <p>We deployed BPHunter retrospectively on the 48 reported pathogenic BP variants and successfully captured 40 of them (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">A</italic></xref>, <xref rid="t02" ref-type="table">Table 2</xref>, <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S17</ext-link>, and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S4</ext-link>). There were 4 deletions (8/17/20/22 nt) that removed the entire BP motif, 2 single-nucleotide deletions that removed one BP site and one BP−2 site, respectively, 22 SNVs that disrupted BP sites, 11 SNVs that disrupted BP−2 sites, and 1 SNV that disrupted a BP−1 site (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">B</italic></xref>). In 24 cases, the variants disrupted the only BP in their 3′-proximal introns, in 9 cases, the variants disrupted the first BP, and in 7 cases, the variants disrupted the nonfirst BP (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">C</italic></xref>). The affected BP comprised 19 mBP, 1 exclusively eBP and 20 exclusively cBP (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">D</italic></xref>). There were 24 BP that matched the YTNAY consensus sequence, whereas the other 8, 7, and 1 BP matched the increasingly relaxed YTNA, TNA, and YNA consensus motifs (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">E</italic></xref>). There were 39 BP positions supported by more than one evidence (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">F</italic></xref>). No population variants were found for 38 BP positions, whereas very rare variants were noted in the other two BP positions (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">G</italic></xref>). The conservation scores GERP and PhyloP were both positive for 33 BP positions and both negative for 5 BP positions (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">H</italic></xref>). We also used two missplicing prediction tools [SpliceAI (<xref rid="r40" ref-type="bibr">40</xref>) and MMSplice (<xref rid="r41" ref-type="bibr">41</xref>)] and a mutation deleteriousness prediction score [CADD (<xref rid="r42" ref-type="bibr">42</xref>)] to evaluate these pathogenic BP variants (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">I</italic></xref>). SpliceAI provides a probability score for altering the acceptor sites (the higher the score, the higher the likelihood of missplicing), and it predicted no variant above its high-precision cutoff of 0.8 (the highest was 0.74), and five variants above its medium cutoff of 0.5. MMSplice provides a score for acceptor disruption (the lower the score, the higher the likelihood of missplicing), and it predicted no variant beyond its suggested cutoff of −2 (the lowest was −1.944). CADD provides a mutation damage score which is heavily reliant on conservation-related metrics. It identified 3 variants having scores &gt;20 (genome-wide top 1%), 26 variants having scores in 10 to 20 (top 1 to 10%), and 11 variants with scores &lt;10. With the use of BPHunter score (introduced in a later section) we found 38/40 variants had score ≥3 (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">J</italic></xref>).</p>
      <fig position="float" id="fig04" fig-type="figure">
        <label>Fig. 4.</label>
        <caption>
          <p>Detection of pathogenic BP variants by BPHunter. (<italic toggle="yes">A</italic>) Timeline of the 48 published pathogenic BP variants (<italic toggle="yes">Left</italic>) and the distance to their 3′ss (<italic toggle="yes">Right</italic>). (<italic toggle="yes">B</italic>) Disrupted positions of BP. (<italic toggle="yes">C</italic>) Ranking of the disrupted BP in its 3′-proximal intron. (<italic toggle="yes">D</italic>) Type of disrupted BP. (<italic toggle="yes">E</italic>) Level of consensus of the disrupted BP motif (1: YTNAY, 2: YTNA, 3: TNA, and 4: YNA). (<italic toggle="yes">F</italic>) Number of data sources supporting the disrupted BP. (<italic toggle="yes">G</italic>) Population variation of the disrupted BP. (<italic toggle="yes">H</italic>) Conservation scores of the disrupted BP. (<italic toggle="yes">I</italic>) Missplicing scores and deleteriousness score of the pathogenic BP variants. (<italic toggle="yes">J</italic>) BPHunter scores of the pathogenic BP variants.</p>
        </caption>
        <graphic xlink:href="pnas.2211194119fig04" position="float"/>
      </fig>
    </sec>
    <sec id="s13">
      <title>Pathogenic BP Variants That BPHunter Did Not Detect.</title>
      <p>BPHunter detected 40/48 reported pathogenic BP variants, leaving 8 variants undetected (<xref rid="t02" ref-type="table">Table 2</xref>), all of which were located very close ([−9, −17] nt) to 3′ss and 6 of which were published before 2004 (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">A</italic></xref>). The eight introns harboring these variants all have BP documented in the BPHunter, but none of these pathogenic variants disrupted the BP. Interestingly, by extracting and aligning their wild-type (wt) and mutated (mt) sequences using SeqTailor (<xref rid="r43" ref-type="bibr">43</xref>), we found that all of them had created an AG-dinucleotide in the region between BP and 3′ss (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S18</ext-link>). By comparing the MaxEnt 3′ss strength (<xref rid="r44" ref-type="bibr">44</xref>) between the constitutional AGs and the created AGs, we found that these eight variants created one stronger 3′ss, six slightly weaker 3′ss, and one unlikely 3′ss. These eight original studies all reported complete/partial exon skipping or intron retention, rather than de novo 3′ss at the created AGs. We therefore hypothesize that the AG-dinucleotides created in the BP-3′ss region may have promoted binding with U2AF35 that recognizes the acceptor site, thereby sterically interfering with the recognition of PPT by U2AF65 and the formation of the spliceosome complex (<xref rid="r45" ref-type="bibr">45</xref>, <xref rid="r46" ref-type="bibr">46</xref>) (<xref rid="fig01" ref-type="fig">Fig. 1<italic toggle="yes">B</italic></xref>). Thus, these eight variants should not be considered as BP variants. Rather, they should be regarded as causing aberrant splicing through the disruption of spliceosome organization on the 3′ side of the intron. BPHunter therefore successfully detected all 40 published pathogenic variants that truly disrupted BP. When these 40 variants were tested with existing cBP datasets, we found that 36, 30, and 37 can be detected using BPP, Branchpointer, and LaBranchoR, respectively. This confirms that the detection output from BPHunter is an inclusive outcome that outperforms the use of any single BP dataset.</p>
    </sec>
    <sec id="s14">
      <title>Comparison of the Pathogenic BP Variants with Common BP Variants in the General Population.</title>
      <p>Focusing on SNVs at BP and BP−2 positions, we compared 33 pathogenic variants (22 variants on BP and 11 variants on BP−2) against 659 common population variants (386 variants on BP and 273 variants on BP−2, with MAF ≥1%) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S19<italic toggle="yes">A</italic></ext-link>). We found that common variants occurred significantly less frequently in 3′-proximal introns with single BP (6%) versus pathogenic variants (58%, <italic toggle="yes">P</italic> &lt; 0.00001 by Fisher’s exact test) and were significantly more frequent in BP of rank ≥3 (28% vs. 2%, <italic toggle="yes">P</italic> value &lt; 0.00001). Thirty-five percent of common variants were located within BP motifs that did not match any level of consensus, which was 0% in pathogenic variants (<italic toggle="yes">P</italic> = 0); 63% of common variants were in BP sites supported by only one source, which was 3% in pathogenic variants (<italic toggle="yes">P</italic> &lt; 0.00001). By contrasting the positively GERP/PhyloP-scored BP positions with the negatively GERP/PhyloP-scored BP positions, common variants (36% vs. 54%) showed significant enrichment (<italic toggle="yes">P</italic> &lt; 0.00001) in having negative conservation scores against pathogenic variants (79% vs. 14%). There were 66% of common variants obtained low BPHunter scores = 0∼2 (the next section), whereas only one pathogenic BP variant was scored ≤2 (<italic toggle="yes">P</italic> &lt; 0.00001). Furthermore, we analyzed the nucleotide changes in BP and BP−2 positions separately. We compared 22 pathogenic variants against 386 common variants at BP positions (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S19<italic toggle="yes">B</italic></ext-link>). A &gt; G was the most frequent (68%) among the pathogenic BP variants (<xref rid="r47" ref-type="bibr">47</xref>) but not statistically significant when compared with common BP variants (51%, <italic toggle="yes">P</italic> = 0.128). We then compared 11 pathogenic variants against 273 common variants at BP−2 positions (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S19<italic toggle="yes">C</italic></ext-link>). The nucleotide changes T &gt; A and T &gt; G were both significantly enriched in pathogenic BP−2 variants against common BP−2 variants (37% vs. 10% with <italic toggle="yes">P</italic> = 0.025 for T &gt; A and 45% vs. 10% with <italic toggle="yes">P</italic> = 0.0038 for T &gt; G). The nucleotide change T &gt; C was the least frequent (18%) in pathogenic BP−2 variants although the most frequent (38%) in common BP−2 variants, albeit not significant (<italic toggle="yes">P</italic> = 0.2198). These statistics were based on the small number of reported pathogenic variants, and with additional BP variants reported in the future this analysis should be refreshed.</p>
    </sec>
    <sec id="s15">
      <title>Strategy for Prioritizing BP Variant Candidates.</title>
      <p>The analysis of the published pathogenic BP variants, in concert with the analysis of common BP variants, helped us to formulate a strategy to prioritize BP variant candidates: 1) deletion of the entire BP motif, or disruption of the BP or BP−2 positions; 2) variant of the only BP in the 3′-promixal intron or the first/second BP in the 3′-promixal intron with no more than three BP; 3) variant in a BP motif matching the consensus YTNAY, while also allowing a slightly relaxed consensus; 4) variant at a BP position with more than one supporting source, regardless of its type (mBP/eBP/cBP); 5) variant at a BP position with no or rare population variants; 6) variant at a BP position with positive-scored GERP or PhyloP may be preferred; and 7) variant C &gt; T or T &gt; C at BP−2 could be deprioritized. We implemented a BPHunter scoring scheme to take account of these important features (<xref rid="fig04" ref-type="fig">Fig. 4<italic toggle="yes">J</italic></xref> and <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S20</ext-link>) to help to prioritize the candidate variants. The score ranges from 0 to 10, with a higher score indicating a higher likelihood of deleteriousness. We recommend a threshold score ≥3 and suggest focusing on SNVs and deletions, as the impact of insertions on splicing is difficult to predict using the current tool. The SpliceAI, MMSplice, and CADD scores could provide additional reference but should not be fully relied upon, particularly when evaluating newly identified BP variants (see our case study of a <italic toggle="yes">STAT2</italic> variant in a critical COVID-19 patient). Additionally, homozygous and hemizygous variants should be prioritized, and candidate variants in genes associated with the disease under study should be prioritized. The sequencing quality and the complexity/repeats of neighboring nucleotides need to be carefully checked. This prioritization strategy will be updated as the number of discovered BP variants increases.</p>
    </sec>
    <sec id="s16">
      <title>A Germline Heterozygous SNV of <italic toggle="yes">STAT2</italic> Disrupts BP and Splicing in a Patient with Critical COVID-19.</title>
      <p>We performed BPHunter on whole-exome sequencing (WES) data from a cohort of 1,035 patients with life-threatening COVID-19 (<xref rid="r48" ref-type="bibr">48</xref>), focusing on 13 genes that have been reported to carry deleterious variants impairing type-I interferon (IFN) production and underlying critical illness (<xref rid="r49" ref-type="bibr">49</xref>). BPHunter detected one heterozygous variant g.56749159T &gt; A (IVS5-24A &gt; T) in <italic toggle="yes">STAT2</italic> that disrupted the only BP (mBP) located −24 nt from 3′ss of intron-5 (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">A</italic></xref>). This BP matched the YTNAY consensus sequence, had a MAF of 6.98e-6, exhibited a GERP of −0.257 and a PhyloP of 0.152, and was supported by five data sources. These features satisfied our prioritization strategy requirements for a promising candidate BP variant, and it had a BPHunter score = 6, even though the missplicing/deleteriousness predictions were not suggestive of its pathogenicity (SpliceAI = 0, MMSplice = −0.4, CADD = 10.1). We therefore hypothesized that this intronic variant might disrupt BP recognition, leading to missplicing of <italic toggle="yes">STAT2</italic> transcripts. To assess its impact on mRNA splicing, we performed an exon trapping assay. Compared to the wild-type control, mRNA extracted from cells transfected with this variant displayed a majority of abnormally spliced <italic toggle="yes">STAT2</italic> transcripts: 6% normal transcripts in the mutant vs. 70% in the control, 82% of complete exon-6 skipping in the mutant vs. 25% in the control, and 4% of complete intron-5 retention in the mutant vs. none in the control (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">B</italic></xref>). We extracted mRNA from whole blood of the patient and a healthy control and amplified the <italic toggle="yes">STAT2</italic> complementary DNA (cDNA) from exon-3 to exon-7/8 boundary. Sanger sequencing of the PCR products following TOPO-TA cloning showed that the patient’s cells had more misspliced transcripts (exon skipping and intron retention) than the healthy control (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">C</italic></xref>). The cDNA from the patient contained 35% unannotated transcripts in GTEx, whereas the control contained 9% of unannotated transcripts (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">D</italic></xref>). We also assessed <italic toggle="yes">STAT2</italic> mRNA by RT-qPCR to estimate the amount of canonical mRNA transcripts extracted from whole blood and observed about half the level in the patient as compared with the control (<xref rid="fig05" ref-type="fig">Fig. 5<italic toggle="yes">E</italic></xref>). If we also consider the misspliced gene products that could have been degraded by NMD (<xref rid="r50" ref-type="bibr">50</xref>), the patient’s cells should carry more aberrantly spliced products. This case study effectively demonstrated the identification of a novel BP variant in <italic toggle="yes">STAT2</italic> from a life-threatening COVID-19 patient and the experimental validation of its biochemical consequences. It also showed that a BP position with a very low level of evolutionary conservation can nevertheless be functional in splicing regulation, and it is for this reason that existing missplicing/deleteriousness predictions are inadequate to identify promising candidate BP variants.</p>
      <fig position="float" id="fig05" fig-type="figure">
        <label>Fig. 5.</label>
        <caption>
          <p>Detection and validation of a germline heterozygous <italic toggle="yes">STAT2</italic> variant which disrupts BP and splicing in a life-threatening COVID-19 patient. (<italic toggle="yes">A</italic>) Detection of a heterozygous <italic toggle="yes">STAT2</italic> variant disrupting BP. (<italic toggle="yes">B</italic>) <italic toggle="yes">STAT2</italic> transcripts and proportions from exon trapping assay in COS-7 cells. (<italic toggle="yes">C</italic>) <italic toggle="yes">STAT2</italic> transcripts and proportions from RNA extracted from whole blood. (<italic toggle="yes">D</italic>) Ratio of the GTEx-annotated transcripts among the total transcripts. (<italic toggle="yes">E</italic>) Estimation of <italic toggle="yes">STAT2</italic> canonical transcripts based on RT-qPCR, measuring <italic toggle="yes">STAT2</italic> mRNA levels in whole blood using two probes spanning intron 5 (probe 5-6) and intron 6 (probe 6-7).</p>
        </caption>
        <graphic xlink:href="pnas.2211194119fig05" position="float"/>
      </fig>
    </sec>
    <sec id="s17">
      <title>A Somatic Intronic 59-nt Deletion of <italic toggle="yes">ITPKB</italic> Removes All Three Potential BP Sites and Leads to the Retention of the Intron in a Lymphoma Patient.</title>
      <p>We performed BPHunter on somatic tumor-specific variant data derived from the whole-genome sequencing (WGS) of 53 diffuse large B-cell lymphoma (DLBCL) tumor samples (<xref rid="r51" ref-type="bibr">51</xref><xref rid="r52" ref-type="bibr"/>–<xref rid="r53" ref-type="bibr">53</xref>). Focusing on a set of 212 lymphoma-associated genes (<xref rid="r51" ref-type="bibr">51</xref>), BPHunter detected one intronic deletion in <italic toggle="yes">ITPKB</italic> that removed 59 nucleotides from intron-3 (g.226835095_226835153del) (<xref rid="fig06" ref-type="fig">Fig. 6<italic toggle="yes">A</italic></xref>). This intron contains three potential BP sites, and the deletion eliminated all of them, suggesting that the <italic toggle="yes">ITPKB</italic> gene product is highly likely to be misspliced in this tumor sample. <italic toggle="yes">ITPKB</italic> has been shown to be a negative regulator of the BCR/NF-κB signaling pathway which is very important for the growth and survival of lymphoma cells (<xref rid="r54" ref-type="bibr">54</xref>). It has also been shown that truncated ITPKB protein boosts PI3K/Akt signaling, which is a key growth-promoting pathway in lymphoma cells (<xref rid="r55" ref-type="bibr">55</xref>). We therefore hypothesized that this intronic deletion would lead to aberrant splicing, resulting in a truncated/decayed <italic toggle="yes">ITPKB</italic> gene product with loss of function/expression, leading to promotion of the growth and proliferation of lymphoma cells in the affected patient. We studied RNA-seq data of this tumor sample derived from the patient, as well as another three tumor biopsies from random DLBCL patients who do not carry this deletion, and observed complete retention of intron-3 specifically in this patient (<xref rid="fig06" ref-type="fig">Fig. 6 <italic toggle="yes">B</italic> and <italic toggle="yes">C</italic></xref>). Hence, we concluded that this intronic deletion, which would have been filtered out in the absence of BPHunter, resulted in aberrant splicing of <italic toggle="yes">ITPKB</italic>, which consequently contributed to the lymphomagenesis in this patient. This case study successfully demonstrated the use of BPHunter for the detection and exploration of somatic variants. In addition, we screened the noncoding somatic variants in COSMIC (<xref rid="r56" ref-type="bibr">56</xref>), focused on 1,148 genes known to be associated with cancer formation and progression (<xref rid="s20" ref-type="sec"><italic toggle="yes">Methods</italic></xref>), and identified 129 candidate variants that may disrupt BP (106 SNVs and 23 deletions, in 101 genes, from 121 patients involving 19 cancer types) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new">Dataset S5</ext-link>).</p>
      <fig position="float" id="fig06" fig-type="figure">
        <label>Fig. 6.</label>
        <caption>
          <p>Detection and validation of a private somatic intronic deletion of <italic toggle="yes">ITPKB</italic> in a lymphoma patient. (<italic toggle="yes">A</italic>) Detection of a somatic intronic 59-nt deletion of <italic toggle="yes">ITPKB</italic> that removed all three BP sites in intron-3. (<italic toggle="yes">B</italic>) RNA-seq reads alignment on <italic toggle="yes">ITPKB</italic> that showed intronic retention in the lymphoma patient carrying this variant but not in the patients without this variant. (<italic toggle="yes">C</italic>) Sashimi plot from the RNA-seq data.</p>
        </caption>
        <graphic xlink:href="pnas.2211194119fig06" position="float"/>
      </fig>
    </sec>
    <sec id="s18">
      <title>Genome-Wide Detection of BP Variants and Validation of Their Consequences from Paired WES and RNA-Seq Data.</title>
      <p>We identified 14 individuals’ RNA-seq data that we previously published in different studies (<xref rid="r30" ref-type="bibr">30</xref>, <xref rid="r48" ref-type="bibr">48</xref>, <xref rid="r57" ref-type="bibr">57</xref><xref rid="r58" ref-type="bibr"/>–<xref rid="r59" ref-type="bibr">59</xref>), whose paired WES data were also available in-house (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Table S9</ext-link>). We used BPHunter for genome-wide detection, retained SNVs and deletions that had BPHunter scores ≥3, removed variants that failed quality checking, and obtained 69 variants to be validated. We checked their corresponding RNA-seq data (in different cell types, under nonstimulation) and found that 39 variants in genes that have no or very low expression, which we discarded for further analysis. Of the remaining 30 variants that had sufficient RNA-seq read coverage, we observed 11 (37%) variants that demonstrated evidence of missplicing (retained intronic reads, exon skipping, and reduced splicing efficiency) (<ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic>, Fig. S21</ext-link>). Cell type-specific missplicing was observed with variant #5, where intronic retention was evident in neurons but not in fibroblasts. It is worth noting that the RNA-seq data used for this validation were generated by different configurations (protocols, cell types, read lengths/depths, and machines), and no NMD inhibitor was used to retain misspliced transcripts. This analysis demonstrated additional BP variants that lead to missplicing consequences at the biochemical level.</p>
    </sec>
  </sec>
  <sec sec-type="discussion" id="s19">
    <title>Discussion</title>
    <p content-type="flushleft">Intronic sequences comprise ∼38% of the human genome, whereas exonic sequences comprise ∼3%. In the search for candidate variants underlying human disease, current approaches mostly focus on nonsynonymous variants in coding regions and variants residing in essential splice sites. If an investigator wishes to screen for candidate variants among the vast number of intronic variants, a combination of approaches may be applied, e.g., testing for enrichment of intronic variants in a case-control study, computing and ranking the deleteriousness/missplicing scores (<xref rid="r40" ref-type="bibr">40</xref><xref rid="r41" ref-type="bibr"/>–<xref rid="r42" ref-type="bibr">42</xref>) of intronic variants, referencing the MAF of population variations (<xref rid="r32" ref-type="bibr">32</xref>, <xref rid="r60" ref-type="bibr">60</xref>), and clustering genetic heterogeneity (presumably deleterious intronic variants together with coding/splice-site variants) underlying physiological homogeneity (<xref rid="r61" ref-type="bibr">61</xref>). However, enrichment of intronic variants relies on having a group of carriers in cases versus controls, so individual variants (albeit functionally impactful) in sporadic cases are rarely captured. Moreover, many variant deleteriousness scores (<xref rid="r42" ref-type="bibr">42</xref>) are heavily reliant upon evolutionary conservation, and splicing has been shown to evolve rapidly with significant differences between species (<xref rid="r36" ref-type="bibr">36</xref>, <xref rid="r37" ref-type="bibr">37</xref>). This suggests that the application of conservation-derived deleteriousness scores to intronic splicing regulatory elements may not be particularly effective, a conclusion supported by our <italic toggle="yes">STAT2</italic> case study. We also showed that missplicing scores (<xref rid="r40" ref-type="bibr">40</xref>, <xref rid="r41" ref-type="bibr">41</xref>) are underpowered to prioritize promising BP variants. Further, even though some intronic variant candidates may be identified, they do not come with the biochemical interpretations that other types of variants do (e.g., missense, stop-gain, essential splice site) to guide investigators in assessing their pathogenicity.</p>
    <p>With BPHunter, we are now able to detect intronic variants that may disrupt BP recognition, and hence splicing and gene expression/function, in a systematic, efficient, and informative manner. It provides an opportunity for medical genetics studies to explore patients’ MPS data more deeply, by identifying candidate BP variants in known disease-associated genes, or alternatively in new and functionally promising candidate genes. It also provides an opportunity to systematically investigate the biomolecular effect of BP variants, at least in some genes, particularly in those 3′-proximal introns containing multiple BP. Such studies will delineate the intron-specific molecular associations between BP and splicing. We expect an increasing number of characterized BP variants, which alongside the characterization of their biochemical consequences and pathophysiological impact which will help us to comprehend BP function and dysfunction, from the positive results standpoint. BPHunter also provides a platform to report BP variants that do not give rise to missplicing, from the standpoint of negative results, which cannot be published but should nevertheless not be neglected. Lessons learned from negative BP variants will feed back valuable input that can be used to determine functional BP in different contexts, which will in turn improve our understanding of genuine BP positions and alternative BP usages, while improving our ability to discover pathogenic BP variants. We have also noted a study of 120 human BP variants (some were their own data, and some were collected from the published literature), in which the authors showed 82 BP variants (from 79 genomic positions) having no missplicing effect (<xref rid="r62" ref-type="bibr">62</xref>). We found that 72/79 of these positions were not documented as BP by BPHunter. Moreover, it should be noted that many of the variants in this paper were misquoted from their cited origins and had no clear experimental validation.</p>
    <p>In this study, we built a comprehensive database of human BP which represents a qualitative and quantitative knowledgebase of BP in the human genome. This BP database is, however, not yet optimal. The eBP are likely to include false-positive BP, caused by mislocation from RNA-seq reads. The cBP would have missed false-negative BP (some real non-adenine-BP for example), as machine-learning methods always learn the major distinguishing features from training data to differentiate between positives and negatives. Regarding the BP consensus sequence, we noted that while only ∼40% of BP motifs matched the long-established YTNAY, most of the remaining BP motifs fitted with relaxed consensus patterns. Our hypothesis I is that BP motifs that fit the relaxed consensus (mostly displaying low binding affinity with snRNA) may have other <italic toggle="yes">cis</italic>-elements (e.g., intronic splicing enhancers) in the vicinity that interact with <italic toggle="yes">trans</italic>-elements with stronger affinity, to guarantee the collaborative organization of the spliceosome necessary for correct splicing (<xref rid="r6" ref-type="bibr">6</xref>). Our hypothesis II is that the definition of the BP consensus sequence could be context-specific (e.g., tissue-, cell-type-, developmental-stage-, or intron-specific or RNA-structure-dependent) to some extent, to meet the highly context-specific physiological requirements of different tissues and cells. A variant that creates a new BP may disrupt splicing as well, but BPHunter cannot detect this in its current form, which suggests one opportunity for improvement. In addition, we are aware of some splicing mechanism studies involving BP: recursive splicing within the intron allowing multistep intron removal (<xref rid="r9" ref-type="bibr">9</xref>), stem-loop structures bringing distal BP closer to 3′ss (<xref rid="r10" ref-type="bibr">10</xref>), stochastic splice site selection leads to kinetic variation in intron removal (<xref rid="r11" ref-type="bibr">11</xref>), closer-to-5′ss BP leading to mutually exclusive splicing (<xref rid="r63" ref-type="bibr">63</xref>), and BP haplotypes associated with alternative splicing (<xref rid="r64" ref-type="bibr">64</xref>). Taken together, these studies present a fascinating glimpse of the complexity of the spliceosome that calls for greater effort in understanding splicing and in investigating splicing-related pathogenesis.</p>
    <p>BPHunter enables the efficient genome-wide detection of candidate BP variants in MPS data. We hope that this tool will help to improve our ability to diagnose human genetic disease. We also anticipate the application of BPHunter to the study of human somatic variants, in cancers for example (<xref rid="r65" ref-type="bibr">65</xref>). Our timely recruitment of BPHunter to screen our COVID-19 cohort directly led to the identification of a novel and deleterious BP variant in the <italic toggle="yes">STAT2</italic> gene from a patient with life-threatening COVID-19, which was immediately tested experimentally to demonstrate its biochemical consequences. Our subsequent application of BPHunter to lymphoma patients also directly led to the detection of an intronic deletion of <italic toggle="yes">ITPKB</italic> that removed all three potential BP sites in that intron leading to its complete retention as evidenced by RNA-seq data. Without BPHunter, neither of these deleterious variants that impaired the function of these key genes in the disease studied would have been picked up by preexisting conventional methods (e.g., missplicing predictions, deleteriousness scores, enrichment tests). BPHunter therefore constitutes not only an important resource that provides us with an improved genome-wide understanding of BP but also a powerful tool that should drive us to discover new BP variants underlying human genetics diseases and traits.</p>
  </sec>
  <sec sec-type="methods" id="s20">
    <title>Methods</title>
    <sec id="s21">
      <title>Collection of Eight Published BP Datasets, Creation of Two New BP Datasets, and Consensus-Guided Positional Adjustment of BP.</title>
      <p>We collected five datasets of experimentally identified BP (<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r15" ref-type="bibr">15</xref><xref rid="r16" ref-type="bibr"/><xref rid="r17" ref-type="bibr"/>–<xref rid="r18" ref-type="bibr">18</xref>) and three datasets of computationally predicted BP (<xref rid="r19" ref-type="bibr">19</xref><xref rid="r20" ref-type="bibr"/>–<xref rid="r21" ref-type="bibr">21</xref>). We created eBP_BPHunter, by analyzing RNA-seq data of three <italic toggle="yes">DBR1</italic>-mutated patients (<xref rid="r30" ref-type="bibr">30</xref>). We created cBP_BPHunter, by developing a high-precision machine-learning model to scan the region [−3, −40] nt of 3′ss. We screened a window of [−2, +2] nt from each raw BP position for consensus sequence matching and adjusted the position to its closest neighbor that perfectly matched the consensus.</p>
    </sec>
    <sec id="s22">
      <title>Human Population Variants.</title>
      <p>We obtained human genetic variants from the gnomAD database (<xref rid="r32" ref-type="bibr">32</xref>) v3.1, which contained 76,156 WGS samples. We extracted the total allele count (AC) and MAF of population variants, which were categorized into singleton (AC = 1), rare (MAF &lt; 1%), and common (MAF ≥ 1%).</p>
    </sec>
    <sec id="s23">
      <title>Variant Deleteriousness and Missplicing Prediction Scores.</title>
      <p>We used CADD v1.6 (<xref rid="r42" ref-type="bibr">42</xref>), which predicts variant deleteriousness. We used two missplicing scores, SpliceAI (<xref rid="r40" ref-type="bibr">40</xref>) and MMSplice (<xref rid="r41" ref-type="bibr">41</xref>), to evaluate the predicted probability of BP variants in disrupting splicing.</p>
    </sec>
    <sec id="s24">
      <title>A Cohort of Patients with Critical COVID-19 and a Cohort of Lymphoma Patients.</title>
      <p>We used the WES data from 1,035 patients with critical COVID-19, which were recruited through The COVID Human Genetic Effort (<xref rid="r48" ref-type="bibr">48</xref>). We also used WGS data from 53 diffuse large B-cell lymphoma patients, whose paired RNA-seq data from the tumor tissues were available (<xref rid="r51" ref-type="bibr">51</xref><xref rid="r52" ref-type="bibr"/>–<xref rid="r53" ref-type="bibr">53</xref>).</p>
      <p>Written informed consent was obtained in the country of residence of each patient, in accordance with local regulations and with institutional review board (IRB) approval. Data analysis was conducted under the approval of the IRB of the Rockefeller University Institutional Review Board in New York.</p>
      <p>The full methods section is available in <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri" xlink:show="new"><italic toggle="yes">SI Appendix</italic></ext-link>.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xlink:href="pnas.2211194119.sapp.pdf" id="d64e3279" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xlink:href="pnas.2211194119.sd01.txt" id="d64e3282" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xlink:href="pnas.2211194119.sd02.txt" id="d64e3285" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xlink:href="pnas.2211194119.sd03.txt" id="d64e3288" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xlink:href="pnas.2211194119.sd04.xlsx" id="d64e3291" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xlink:href="pnas.2211194119.sd06.pdf" id="d64e3294" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data">
      <label>Supplementary File</label>
      <media xlink:href="pnas.2211194119.sd05.xlsx" id="d64e3297" position="anchor"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>We thank Y. Nemirovskaya, M. Woollett, L. Lorenzo, D. Liu, and E. Williams for administrative support; A. Cobat, E. Jouanguy, and S. Boisson-Dupuis for assistance; and Z. Yang and Y. Nemirovskaya for artwork design. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the NIH (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), ANR grants (ANR-14-CE14-0008-01, ANR-18-CE15-0020-02, and ANR-20-CO11-0001), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), a Fast Grant from Emergent Ventures, Mercatus Center at George Mason University, the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the FRM and ANR GENCOVID project (ANR-20-COVI-0003), ANRS Nord-Sud (ANRS-COV05), the Square Foundation, Grandir-Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, The Foundation du Souffle, Institut National de la Santé et de la Recherche Médicale (INSERM) and the Paris Cité University. We also thank the Swedish Cancer Society (Cancerfonden), the Swedish Research Council, Radiumhemmets, the Center for Innovative Medicine (CIMED), and the Knut and Alice Wallenberg Foundation.</p>
  </ack>
  <fn-group>
    <fn id="fn3" fn-type="other">
      <p>Reviewers: W.F., Brown University; and S.A., University of Geneva Medical School.</p>
    </fn>
    <fn id="fn4" fn-type="COI-statement">
      <p>The authors declare no conflict of interests.</p>
    </fn>
    <fn id="fn96" fn-type="supplementary-material">
      <p>This article contains supporting information online at <ext-link xlink:href="https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental" ext-link-type="uri">https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2211194119/-/DCSupplemental</ext-link>.</p>
    </fn>
  </fn-group>
  <sec sec-type="data-availability" id="s26">
    <title>Data, Materials, and Software Availability</title>
    <p>BPHunter datasets and software are publicly accessible from <ext-link xlink:href="https://hgidsoft.rockefeller.edu/BPHunter" ext-link-type="uri">https://hgidsoft.rockefeller.edu/BPHunter</ext-link> (<xref rid="r66" ref-type="bibr">66</xref>) and <ext-link xlink:href="https://github.com/casanova-lab/BPHunter" ext-link-type="uri">https://github.com/casanova-lab/BPHunter</ext-link> (<xref rid="r67" ref-type="bibr">67</xref>), under CC BY-NC-ND 4.0 License. All other study data are included in the article and/or supporting information.</p>
  </sec>
  <ref-list>
    <ref id="r1">
      <label>1</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M. M.</given-names><surname>Scotti</surname></string-name>, <string-name><given-names>M. S.</given-names><surname>Swanson</surname></string-name></person-group>, <article-title>RNA mis-splicing in disease</article-title>. <source>Nat. Rev. Genet.</source><volume>17</volume>, <fpage>19</fpage>–<lpage>32</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">26593421</pub-id></mixed-citation>
    </ref>
    <ref id="r2">
      <label>2</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G. S.</given-names><surname>Wang</surname></string-name>, <string-name><given-names>T. A.</given-names><surname>Cooper</surname></string-name></person-group>, <article-title>Splicing in disease: Disruption of the splicing code and the decoding machinery</article-title>. <source>Nat. Rev. Genet.</source><volume>8</volume>, <fpage>749</fpage>–<lpage>761</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17726481</pub-id></mixed-citation>
    </ref>
    <ref id="r3">
      <label>3</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. A.</given-names><surname>Sharp</surname></string-name></person-group>, <article-title>Splicing of messenger RNA precursors</article-title>. <source>Science</source><volume>235</volume>, <fpage>766</fpage>–<lpage>771</lpage> (<year>1987</year>).<pub-id pub-id-type="pmid">3544217</pub-id></mixed-citation>
    </ref>
    <ref id="r4">
      <label>4</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names><surname>Gao</surname></string-name>, <string-name><given-names>A.</given-names><surname>Masuda</surname></string-name>, <string-name><given-names>T.</given-names><surname>Matsuura</surname></string-name>, <string-name><given-names>K.</given-names><surname>Ohno</surname></string-name></person-group>, <article-title>Human branch point consensus sequence is yUnAy</article-title>. <source>Nucleic Acids Res.</source><volume>36</volume>, <fpage>2257</fpage>–<lpage>2267</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18285363</pub-id></mixed-citation>
    </ref>
    <ref id="r5">
      <label>5</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. R.</given-names><surname>Mercer</surname></string-name><etal/></person-group>, <article-title>Genome-wide discovery of human splicing branchpoints</article-title>. <source>Genome Res.</source><volume>25</volume>, <fpage>290</fpage>–<lpage>303</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25561518</pub-id></mixed-citation>
    </ref>
    <ref id="r6">
      <label>6</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Tholen</surname></string-name>, <string-name><given-names>M.</given-names><surname>Razew</surname></string-name>, <string-name><given-names>F.</given-names><surname>Weis</surname></string-name>, <string-name><given-names>W. P.</given-names><surname>Galej</surname></string-name></person-group>, <article-title>Structural basis of branch site recognition by the human spliceosome</article-title>. <source>Science</source><volume>375</volume>, <fpage>50</fpage>–<lpage>57</lpage> (<year>2022</year>).<pub-id pub-id-type="pmid">34822310</pub-id></mixed-citation>
    </ref>
    <ref id="r7">
      <label>7</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. J.</given-names><surname>Turunen</surname></string-name>, <string-name><given-names>E. H.</given-names><surname>Niemelä</surname></string-name>, <string-name><given-names>B.</given-names><surname>Verma</surname></string-name>, <string-name><given-names>M. J.</given-names><surname>Frilander</surname></string-name></person-group>, <article-title>The significant other: Splicing by the minor spliceosome</article-title>. <source>Wiley Interdiscip. Rev. RNA</source><volume>4</volume>, <fpage>61</fpage>–<lpage>76</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23074130</pub-id></mixed-citation>
    </ref>
    <ref id="r8">
      <label>8</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names><surname>Bai</surname></string-name><etal/></person-group>, <article-title>Structure of the activated human minor spliceosome</article-title>. <source>Science</source><volume>371</volume>, <fpage>eabg0879</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33509932</pub-id></mixed-citation>
    </ref>
    <ref id="r9">
      <label>9</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. R.</given-names><surname>Sibley</surname></string-name><etal/></person-group>, <article-title>Recursive splicing in long vertebrate genes</article-title>. <source>Nature</source><volume>521</volume>, <fpage>371</fpage>–<lpage>375</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25970246</pub-id></mixed-citation>
    </ref>
    <ref id="r10">
      <label>10</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. L.</given-names><surname>Lin</surname></string-name>, <string-name><given-names>A. J.</given-names><surname>Taggart</surname></string-name>, <string-name><given-names>W. G.</given-names><surname>Fairbrother</surname></string-name></person-group>, <article-title>RNA structure in splicing: An evolutionary perspective</article-title>. <source>RNA Biol.</source><volume>13</volume>, <fpage>766</fpage>–<lpage>771</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27454491</pub-id></mixed-citation>
    </ref>
    <ref id="r11">
      <label>11</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Y.</given-names><surname>Wan</surname></string-name><etal/></person-group>, <article-title>Dynamic imaging of nascent RNA reveals general principles of transcription dynamics and stochastic splice site selection</article-title>. <source>Cell</source><volume>184</volume>, <fpage>2878</fpage>–<lpage>2895.e20</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33979654</pub-id></mixed-citation>
    </ref>
    <ref id="r12">
      <label>12</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. R.</given-names><surname>Awan</surname></string-name>, <string-name><given-names>A.</given-names><surname>Manfredo</surname></string-name>, <string-name><given-names>J. A.</given-names><surname>Pleiss</surname></string-name></person-group>, <article-title>Lariat sequencing in a unicellular yeast identifies regulated alternative splicing of exons that are evolutionarily conserved with humans</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>110</volume>, <fpage>12762</fpage>–<lpage>12767</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23861491</pub-id></mixed-citation>
    </ref>
    <ref id="r13">
      <label>13</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names><surname>Chen</surname></string-name><etal/></person-group>, <article-title>Transcriptome-wide interrogation of the functional intronome by spliceosome profiling</article-title>. <source>Cell</source><volume>173</volume>, <fpage>1031</fpage>–<lpage>1044.e13</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29727662</pub-id></mixed-citation>
    </ref>
    <ref id="r14">
      <label>14</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. J.</given-names><surname>Taggart</surname></string-name>, <string-name><given-names>A. M.</given-names><surname>DeSimone</surname></string-name>, <string-name><given-names>J. S.</given-names><surname>Shih</surname></string-name>, <string-name><given-names>M. E.</given-names><surname>Filloux</surname></string-name>, <string-name><given-names>W. G.</given-names><surname>Fairbrother</surname></string-name></person-group>, <article-title>Large-scale mapping of branchpoints in human pre-mRNA transcripts in vivo</article-title>. <source>Nat. Struct. Mol. Biol.</source><volume>19</volume>, <fpage>719</fpage>–<lpage>721</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22705790</pub-id></mixed-citation>
    </ref>
    <ref id="r15">
      <label>15</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. J.</given-names><surname>Taggart</surname></string-name><etal/></person-group>, <article-title>Large-scale analysis of branchpoint usage across species and cell lines</article-title>. <source>Genome Res.</source><volume>27</volume>, <fpage>639</fpage>–<lpage>649</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28119336</pub-id></mixed-citation>
    </ref>
    <ref id="r16">
      <label>16</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. M. B.</given-names><surname>Pineda</surname></string-name>, <string-name><given-names>R. K.</given-names><surname>Bradley</surname></string-name></person-group>, <article-title>Most human introns are recognized via multiple and tissue-specific branchpoints</article-title>. <source>Genes Dev.</source><volume>32</volume>, <fpage>577</fpage>–<lpage>591</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29666160</pub-id></mixed-citation>
    </ref>
    <ref id="r17">
      <label>17</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G. J. S.</given-names><surname>Talhouarne</surname></string-name>, <string-name><given-names>J. G.</given-names><surname>Gall</surname></string-name></person-group>, <article-title>Lariat intronic RNAs in the cytoplasm of vertebrate cells</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>115</volume>, <fpage>E7970</fpage>–<lpage>E7977</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30082412</pub-id></mixed-citation>
    </ref>
    <ref id="r18">
      <label>18</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Briese</surname></string-name><etal/></person-group>, <article-title>A systems view of spliceosomal assembly and branchpoints with iCLIP</article-title>. <source>Nat. Struct. Mol. Biol.</source><volume>26</volume>, <fpage>930</fpage>–<lpage>940</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31570875</pub-id></mixed-citation>
    </ref>
    <ref id="r19">
      <label>19</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, <article-title>BPP: A sequence-based algorithm for branch point prediction</article-title>. <source>Bioinformatics</source><volume>33</volume>, <fpage>3166</fpage>–<lpage>3172</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28633445</pub-id></mixed-citation>
    </ref>
    <ref id="r20">
      <label>20</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>B.</given-names><surname>Signal</surname></string-name>, <string-name><given-names>B. S.</given-names><surname>Gloss</surname></string-name>, <string-name><given-names>M. E.</given-names><surname>Dinger</surname></string-name>, <string-name><given-names>T. R.</given-names><surname>Mercer</surname></string-name></person-group>, <article-title>Machine learning annotation of human branchpoints</article-title>. <source>Bioinformatics</source><volume>34</volume>, <fpage>920</fpage>–<lpage>927</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29092009</pub-id></mixed-citation>
    </ref>
    <ref id="r21">
      <label>21</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. M.</given-names><surname>Paggi</surname></string-name>, <string-name><given-names>G.</given-names><surname>Bejerano</surname></string-name></person-group>, <article-title>A sequence-based, deep learning model accurately predicts RNA splicing branchpoints</article-title>. <source>RNA</source><volume>24</volume>, <fpage>1647</fpage>–<lpage>1658</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30224349</pub-id></mixed-citation>
    </ref>
    <ref id="r22">
      <label>22</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T. A.</given-names><surname>Cooper</surname></string-name>, <string-name><given-names>L.</given-names><surname>Wan</surname></string-name>, <string-name><given-names>G.</given-names><surname>Dreyfuss</surname></string-name></person-group>, <article-title>RNA and disease</article-title>. <source>Cell</source><volume>136</volume>, <fpage>777</fpage>–<lpage>793</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19239895</pub-id></mixed-citation>
    </ref>
    <ref id="r23">
      <label>23</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R. K.</given-names><surname>Singh</surname></string-name>, <string-name><given-names>T. A.</given-names><surname>Cooper</surname></string-name></person-group>, <article-title>Pre-mRNA splicing in disease and therapeutics</article-title>. <source>Trends Mol. Med.</source><volume>18</volume>, <fpage>472</fpage>–<lpage>482</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22819011</pub-id></mixed-citation>
    </ref>
    <ref id="r24">
      <label>24</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S.</given-names><surname>Bao</surname></string-name>, <string-name><given-names>D. F.</given-names><surname>Moakley</surname></string-name>, <string-name><given-names>C.</given-names><surname>Zhang</surname></string-name></person-group>, <article-title>The splicing code goes deep</article-title>. <source>Cell</source><volume>176</volume>, <fpage>414</fpage>–<lpage>416</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30682368</pub-id></mixed-citation>
    </ref>
    <ref id="r25">
      <label>25</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P. D.</given-names><surname>Stenson</surname></string-name><etal/></person-group>, <article-title>The Human Gene Mutation Database (HGMD<sup>®</sup>): Optimizing its use in a clinical diagnostic or research setting</article-title>. <source>Hum. Genet.</source><volume>139</volume>, <fpage>1197</fpage>–<lpage>1207</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32596782</pub-id></mixed-citation>
    </ref>
    <ref id="r26">
      <label>26</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>T.</given-names><surname>Sterne-Weiler</surname></string-name>, <string-name><given-names>J.</given-names><surname>Howard</surname></string-name>, <string-name><given-names>M.</given-names><surname>Mort</surname></string-name>, <string-name><given-names>D. N.</given-names><surname>Cooper</surname></string-name>, <string-name><given-names>J. R.</given-names><surname>Sanford</surname></string-name></person-group>, <article-title>Loss of exon identity is a common mechanism of human inherited disease</article-title>. <source>Genome Res.</source><volume>21</volume>, <fpage>1563</fpage>–<lpage>1571</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21750108</pub-id></mixed-citation>
    </ref>
    <ref id="r27">
      <label>27</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>L. S.</given-names><surname>Kremer</surname></string-name><etal/></person-group>, <article-title>Genetic diagnosis of Mendelian disorders via RNA sequencing</article-title>. <source>Nat. Commun.</source><volume>8</volume>, <fpage>15824</fpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28604674</pub-id></mixed-citation>
    </ref>
    <ref id="r28">
      <label>28</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. N.</given-names><surname>Cooper</surname></string-name></person-group>, <article-title>Functional intronic polymorphisms: Buried treasure awaiting discovery within our genes</article-title>. <source>Hum. Genomics</source><volume>4</volume>, <fpage>284</fpage>–<lpage>288</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20650817</pub-id></mixed-citation>
    </ref>
    <ref id="r29">
      <label>29</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A.</given-names><surname>Rosenthal</surname></string-name>, <string-name><given-names>M.</given-names><surname>Jouet</surname></string-name>, <string-name><given-names>S.</given-names><surname>Kenwrick</surname></string-name></person-group>, <article-title>Aberrant splicing of neural cell adhesion molecule L1 mRNA in a family with X-linked hydrocephalus</article-title>. <source>Nat. Genet.</source><volume>2</volume>, <fpage>107</fpage>–<lpage>112</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1303258</pub-id></mixed-citation>
    </ref>
    <ref id="r30">
      <label>30</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. Y.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, <article-title>Inborn errors of RNA lariat metabolism in humans with brainstem viral infection</article-title>. <source>Cell</source><volume>172</volume>, <fpage>952</fpage>–<lpage>965.e18</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29474921</pub-id></mixed-citation>
    </ref>
    <ref id="r31">
      <label>31</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>A. B.</given-names><surname>Rosenberg</surname></string-name>, <string-name><given-names>R. P.</given-names><surname>Patwardhan</surname></string-name>, <string-name><given-names>J.</given-names><surname>Shendure</surname></string-name>, <string-name><given-names>G.</given-names><surname>Seelig</surname></string-name></person-group>, <article-title>Learning the sequence determinants of alternative splicing from millions of random sequences</article-title>. <source>Cell</source><volume>163</volume>, <fpage>698</fpage>–<lpage>711</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26496609</pub-id></mixed-citation>
    </ref>
    <ref id="r32">
      <label>32</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. J.</given-names><surname>Karczewski</surname></string-name><etal/></person-group>; <collab>Genome Aggregation Database Consortium</collab>, <article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>. <source>Nature</source><volume>581</volume>, <fpage>434</fpage>–<lpage>443</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32461654</pub-id></mixed-citation>
    </ref>
    <ref id="r33">
      <label>33</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G. M.</given-names><surname>Cooper</surname></string-name><etal/></person-group>; <collab>NISC Comparative Sequencing Program</collab>, <article-title>Distribution and intensity of constraint in mammalian genomic sequence</article-title>. <source>Genome Res.</source><volume>15</volume>, <fpage>901</fpage>–<lpage>913</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15965027</pub-id></mixed-citation>
    </ref>
    <ref id="r34">
      <label>34</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K. S.</given-names><surname>Pollard</surname></string-name>, <string-name><given-names>M. J.</given-names><surname>Hubisz</surname></string-name>, <string-name><given-names>K. R.</given-names><surname>Rosenbloom</surname></string-name>, <string-name><given-names>A.</given-names><surname>Siepel</surname></string-name></person-group>, <article-title>Detection of nonneutral substitution rates on mammalian phylogenies</article-title>. <source>Genome Res.</source><volume>20</volume>, <fpage>110</fpage>–<lpage>121</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">19858363</pub-id></mixed-citation>
    </ref>
    <ref id="r35">
      <label>35</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>N. K.</given-names><surname>Kadri</surname></string-name>, <string-name><given-names>X. M.</given-names><surname>Mapel</surname></string-name>, <string-name><given-names>H.</given-names><surname>Pausch</surname></string-name></person-group>, <article-title>The intronic branch point sequence is under strong evolutionary constraint in the bovine and human genome</article-title>. <source>Commun. Biol.</source><volume>4</volume>, <fpage>1206</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34675361</pub-id></mixed-citation>
    </ref>
    <ref id="r36">
      <label>36</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names><surname>Keren</surname></string-name>, <string-name><given-names>G.</given-names><surname>Lev-Maor</surname></string-name>, <string-name><given-names>G.</given-names><surname>Ast</surname></string-name></person-group>, <article-title>Alternative splicing and evolution: Diversification, exon definition and function</article-title>. <source>Nat. Rev. Genet.</source><volume>11</volume>, <fpage>345</fpage>–<lpage>355</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20376054</pub-id></mixed-citation>
    </ref>
    <ref id="r37">
      <label>37</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Xiong</surname></string-name><etal/></person-group>, <article-title>Predominant patterns of splicing evolution on human, chimpanzee and macaque evolutionary lineages</article-title>. <source>Hum. Mol. Genet.</source><volume>27</volume>, <fpage>1474</fpage>–<lpage>1485</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29452398</pub-id></mixed-citation>
    </ref>
    <ref id="r38">
      <label>38</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>H.</given-names><surname>Ellegren</surname></string-name></person-group>, <article-title>The different levels of genetic diversity in sex chromosomes and autosomes</article-title>. <source>Trends Genet.</source><volume>25</volume>, <fpage>278</fpage>–<lpage>284</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19481288</pub-id></mixed-citation>
    </ref>
    <ref id="r39">
      <label>39</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>D. M.</given-names><surname>Canson</surname></string-name><etal/></person-group>, <article-title>The splicing effect of variants at branchpoint elements in cancer genes</article-title>. <source>Genet. Med.</source><ext-link xlink:href="http://10.1016/j.gim.2021.09.020" ext-link-type="uri">10.1016/j.gim.2021.09.020</ext-link> (<year>2021</year>).</mixed-citation>
    </ref>
    <ref id="r40">
      <label>40</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names><surname>Jaganathan</surname></string-name><etal/></person-group>, <article-title>Predicting splicing from primary sequence with deep learning</article-title>. <source>Cell</source><volume>176</volume>, <fpage>535</fpage>–<lpage>548.e24</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30661751</pub-id></mixed-citation>
    </ref>
    <ref id="r41">
      <label>41</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Cheng</surname></string-name><etal/></person-group>, <article-title>MMSplice: Modular modeling improves the predictions of genetic variant effects on splicing</article-title>. <source>Genome Biol.</source><volume>20</volume>, <fpage>48</fpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30823901</pub-id></mixed-citation>
    </ref>
    <ref id="r42">
      <label>42</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Rentzsch</surname></string-name>, <string-name><given-names>D.</given-names><surname>Witten</surname></string-name>, <string-name><given-names>G. M.</given-names><surname>Cooper</surname></string-name>, <string-name><given-names>J.</given-names><surname>Shendure</surname></string-name>, <string-name><given-names>M.</given-names><surname>Kircher</surname></string-name></person-group>, <article-title>CADD: Predicting the deleteriousness of variants throughout the human genome</article-title>. <source>Nucleic Acids Res.</source><volume>47</volume> (<issue>D1</issue>), <fpage>D886</fpage>–<lpage>D894</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30371827</pub-id></mixed-citation>
    </ref>
    <ref id="r43">
      <label>43</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, <article-title>SeqTailor: A user-friendly webserver for the extraction of DNA or protein sequences from next-generation sequencing data</article-title>. <source>Nucleic Acids Res.</source><volume>47</volume> (<issue>W1</issue>), <fpage>W623</fpage>–<lpage>W631</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31045209</pub-id></mixed-citation>
    </ref>
    <ref id="r44">
      <label>44</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>G.</given-names><surname>Yeo</surname></string-name>, <string-name><given-names>C. B.</given-names><surname>Burge</surname></string-name></person-group>, <article-title>Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals</article-title>. <source>J. Comput. Biol.</source><volume>11</volume>, <fpage>377</fpage>–<lpage>394</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15285897</pub-id></mixed-citation>
    </ref>
    <ref id="r45">
      <label>45</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names><surname>Wimmer</surname></string-name><etal/></person-group>, <article-title>AG-exclusion zone revisited: Lessons to learn from 91 intronic NF1 3′ splice site mutations outside the canonical AG-dinucleotides</article-title>. <source>Hum. Mutat.</source><volume>41</volume>, <fpage>1145</fpage>–<lpage>1156</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32126153</pub-id></mixed-citation>
    </ref>
    <ref id="r46">
      <label>46</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>S. J.</given-names><surname>Bryen</surname></string-name><etal/></person-group>, <article-title>Prevalence, parameters, and pathogenic mechanisms for splice-altering acceptor variants that disrupt the AG exclusion zone</article-title>. <source>HGG Adv</source><volume>3</volume>, <fpage>100125</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">35847480</pub-id></mixed-citation>
    </ref>
    <ref id="r47">
      <label>47</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Královicová</surname></string-name>, <string-name><given-names>H.</given-names><surname>Lei</surname></string-name>, <string-name><given-names>I.</given-names><surname>Vorechovský</surname></string-name></person-group>, <article-title>Phenotypic consequences of branch point substitutions</article-title>. <source>Hum. Mutat.</source><volume>27</volume>, <fpage>803</fpage>–<lpage>813</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16835862</pub-id></mixed-citation>
    </ref>
    <ref id="r48">
      <label>48</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. L.</given-names><surname>Casanova</surname></string-name>, <string-name><given-names>H. C.</given-names><surname>Su</surname></string-name></person-group>, <collab>COVID Human Genetic Effort</collab>, <article-title>A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection</article-title>. <source>Cell</source><volume>181</volume>, <fpage>1194</fpage>–<lpage>1199</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32405102</pub-id></mixed-citation>
    </ref>
    <ref id="r49">
      <label>49</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>Q.</given-names><surname>Zhang</surname></string-name><etal/></person-group>; <collab>COVID-STORM Clinicians</collab>; <collab>COVID Clinicians</collab>; <collab>Imagine COVID Group</collab>; <collab>French COVID Cohort Study Group</collab>; <collab>CoV-Contact Cohort</collab>; <collab>Amsterdam UMC Covid-19 Biobank</collab>; <collab>COVID Human Genetic Effort</collab>; <collab>NIAID-USUHS/TAGC COVID Immunity Group</collab>, <article-title>Inborn errors of type I IFN immunity in patients with life-threatening COVID-19</article-title>. <source>Science</source><volume>370</volume>, <fpage>eabd4570</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32972995</pub-id></mixed-citation>
    </ref>
    <ref id="r50">
      <label>50</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>F.</given-names><surname>Häuser</surname></string-name><etal/></person-group>, <article-title>A non-invasive diagnostic assay for rapid detection and characterization of aberrant mRNA-splicing by nonsense mediated decay inhibition</article-title>. <source>Mol. Genet. Metab.</source><volume>130</volume>, <fpage>27</fpage>–<lpage>35</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32222271</pub-id></mixed-citation>
    </ref>
    <ref id="r51">
      <label>51</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>W.</given-names><surname>Ren</surname></string-name><etal/></person-group>, <article-title>Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma</article-title>. <source>Blood</source><volume>131</volume>, <fpage>2670</fpage>–<lpage>2681</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29545328</pub-id></mixed-citation>
    </ref>
    <ref id="r52">
      <label>52</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>X.</given-names><surname>Ye</surname></string-name><etal/></person-group>, <article-title>Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas</article-title>. <source>J. Exp. Med.</source><volume>218</volume>, <fpage>e20200573</fpage> (<year>2021</year>).<pub-id pub-id-type="pmid">33136155</pub-id></mixed-citation>
    </ref>
    <ref id="r53">
      <label>53</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>K.</given-names><surname>Georgiou</surname></string-name><etal/></person-group>, <article-title>Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas</article-title>. <source>Blood</source><volume>127</volume>, <fpage>3026</fpage>–<lpage>3034</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27030389</pub-id></mixed-citation>
    </ref>
    <ref id="r54">
      <label>54</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names><surname>Schmitz</surname></string-name><etal/></person-group>, <article-title>Genetics and pathogenesis of diffuse large B-cell lymphoma</article-title>. <source>N. Engl. J. Med.</source><volume>378</volume>, <fpage>1396</fpage>–<lpage>1407</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29641966</pub-id></mixed-citation>
    </ref>
    <ref id="r55">
      <label>55</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>E.</given-names><surname>Tiacci</surname></string-name><etal/></person-group>, <article-title>Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma</article-title>. <source>Blood</source><volume>131</volume>, <fpage>2454</fpage>–<lpage>2465</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">29650799</pub-id></mixed-citation>
    </ref>
    <ref id="r56">
      <label>56</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J. G.</given-names><surname>Tate</surname></string-name><etal/></person-group>, <article-title>COSMIC: The catalogue of somatic mutations in cancer</article-title>. <source>Nucleic Acids Res.</source><volume>47</volume> (<issue>D1</issue>), <fpage>D941</fpage>–<lpage>D947</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">30371878</pub-id></mixed-citation>
    </ref>
    <ref id="r57">
      <label>57</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>F. G.</given-names><surname>Lafaille</surname></string-name><etal/></person-group>, <article-title>Human SNORA31 variations impair cortical neuron-intrinsic immunity to HSV-1 and underlie herpes simplex encephalitis</article-title>. <source>Nat. Med.</source><volume>25</volume>, <fpage>1873</fpage>–<lpage>1884</lpage> (<year>2019</year>).<pub-id pub-id-type="pmid">31806906</pub-id></mixed-citation>
    </ref>
    <ref id="r58">
      <label>58</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Bastard</surname></string-name><etal/></person-group>, <article-title>Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency</article-title>. <source>J. Clin. Invest.</source><volume>131</volume>, <fpage>e139980</fpage> (<year>2021</year>).</mixed-citation>
    </ref>
    <ref id="r59">
      <label>59</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>M.</given-names><surname>Ogishi</surname></string-name><etal/></person-group>, <article-title>Impaired IL-23-dependent induction of IFN-γ underlies mycobacterial disease in patients with inherited TYK2 deficiency</article-title>. <source>J. Exp. Med.</source><volume>219</volume>, <fpage>e20220094</fpage> (<year>2022</year>).<pub-id pub-id-type="pmid">36094518</pub-id></mixed-citation>
    </ref>
    <ref id="r60">
      <label>60</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, <article-title>PopViz: A webserver for visualizing minor allele frequencies and damage prediction scores of human genetic variations</article-title>. <source>Bioinformatics</source><volume>34</volume>, <fpage>4307</fpage>–<lpage>4309</lpage> (<year>2018</year>).<pub-id pub-id-type="pmid">30535305</pub-id></mixed-citation>
    </ref>
    <ref id="r61">
      <label>61</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, <article-title>A computational approach for detecting physiological homogeneity in the midst of genetic heterogeneity</article-title>. <source>Am. J. Hum. Genet.</source><volume>108</volume>, <fpage>1012</fpage>–<lpage>1025</lpage> (<year>2021</year>).<pub-id pub-id-type="pmid">34015270</pub-id></mixed-citation>
    </ref>
    <ref id="r62">
      <label>62</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>R.</given-names><surname>Leman</surname></string-name><etal/></person-group>, <article-title>Assessment of branch point prediction tools to predict physiological branch points and their alteration by variants</article-title>. <source>BMC Genomics</source><volume>21</volume>, <fpage>86</fpage> (<year>2020</year>).<pub-id pub-id-type="pmid">31992191</pub-id></mixed-citation>
    </ref>
    <ref id="r63">
      <label>63</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C. W.</given-names><surname>Smith</surname></string-name>, <string-name><given-names>B.</given-names><surname>Nadal-Ginard</surname></string-name></person-group>, <article-title>Mutually exclusive splicing of alpha-tropomyosin exons enforced by an unusual lariat branch point location: Implications for constitutive splicing</article-title>. <source>Cell</source><volume>56</volume>, <fpage>749</fpage>–<lpage>758</lpage> (<year>1989</year>).<pub-id pub-id-type="pmid">2924347</pub-id></mixed-citation>
    </ref>
    <ref id="r64">
      <label>64</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>J.</given-names><surname>Královicová</surname></string-name>, <string-name><given-names>S.</given-names><surname>Houngninou-Molango</surname></string-name>, <string-name><given-names>A.</given-names><surname>Krämer</surname></string-name>, <string-name><given-names>I.</given-names><surname>Vorechovsky</surname></string-name></person-group>, <article-title>Branch site haplotypes that control alternative splicing</article-title>. <source>Hum. Mol. Genet.</source><volume>13</volume>, <fpage>3189</fpage>–<lpage>3202</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15496424</pub-id></mixed-citation>
    </ref>
    <ref id="r65">
      <label>65</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><given-names>C.</given-names><surname>Calabrese</surname></string-name><etal/></person-group>; <collab>PCAWG Transcriptome Core Group</collab>; <collab>PCAWG Transcriptome Working Group</collab>; <collab>PCAWG Consortium</collab>, <article-title>Genomic basis for RNA alterations in cancer</article-title>. <source>Nature</source><volume>578</volume>, <fpage>129</fpage>–<lpage>136</lpage> (<year>2020</year>).<pub-id pub-id-type="pmid">32025019</pub-id></mixed-citation>
    </ref>
    <ref id="r66">
      <label>66</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, BPHunter. <ext-link xlink:href="https://hgidsoft.rockefeller.edu/BPHunter/" ext-link-type="uri">https://hgidsoft.rockefeller.edu/BPHunter/</ext-link>. Accessed 17 October 2022.</mixed-citation>
    </ref>
    <ref id="r67">
      <label>67</label>
      <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><given-names>P.</given-names><surname>Zhang</surname></string-name><etal/></person-group>, BPHunter, Genome-wide detection of human variants that disrupt intronic branchpoints. GitHub. <ext-link xlink:href="https://github.com/casanova-lab/BPHunter" ext-link-type="uri">https://github.com/casanova-lab/BPHunter</ext-link>. Deposited 8 January 2022.</mixed-citation>
    </ref>
  </ref-list>
</back>
